MSH|^~&\|BioRefHMODownload-H|BIO-REFERENCE LABS|02/01/2013 -> 02/01/2013|1200239^|201302011340||ORU^R01|20130201134016.1|P|2.5|1||NE|NEPID|1||107311769|10389866       |MARY^JANE||19231101|F|||367 91 ST^^BROOKLYN^NY^11209||3472604473||||||OBR|1|10389866       |107691769|0009-1^Lipid Screen(Basic Lipid Profile)||201204180000|201204180000|||||||201204182334||H53870^FARHAT^LAILA^|(718)213-4287|80061||BIOREFERENCE LABORATORIES||201204191358|||F||||OBX|1|NM|0058-8^Cholesterol^BRLI^2093-3^CHOLESTEROL^LOINC||166|mg/dL|<200||||F||82465|201204191358OBX|2|NM|0059-6^HDL CHOL., DIRECT^BRLI^2085-9^CHOLESTEROL.IN HDL^LOINC||54||>40||||F||83718|201204191358OBX|3|NM|0155-2^Triglycerides^BRLI^2571-8^TRIGLYCERIDE^LOINC||178|mg/dL|<150|H|||F||84478|201204191358OBX|4|NM|1764-0^HDL as % of Cholesterol^BRLI^2095-8^CHOLESTEROL.IN HDL/CHOLESTEROL.TOTAL^LOINC||33|%|>14||||F|||201204191358NTE|1|L|Evaluation: BELOW AVERAGE RISKOBX|5|NM|1421-7^Chol/HDL Ratio^BRLI^9830-1^CHOLESTEROL.TOTAL/CHOLESTEROL.IN HDL^LOINC||3.1||<7.4||||F|||201204191358NTE|1|L|Evaluation: BELOW AVERAGE RISKOBX|6|NM|0253-5^LDL/HDL Ratio^BRLI^11054-4^CHOLESTEROL.IN LDL/CHOLESTEROL.IN HDL^LOINC||1.41||<3.56||||F|||201204191358OBX|7|NM|0505-8^LDL Cholesterol^BRLI^2089-1^CHOLESTEROL.IN LDL^LOINC||76|mg/dL|<100||||F||83720|201204191358OBX|8|NM|3345-6^VLDL, CALCULATED^BRLI^^^LOINC||36|mg/dL|7-32|H|||F||99999|201204191358OBR|2|10389866       |107691769|0102-4^Hemoglobin A1C (Glycohgb)||201204180000|201204180000|||||||201204182334||H53870^FARHAT^LAILA^|(718)238-4287|83036||BIOREFERENCE LABORATORIES||201204191358|||F||||OBX|1|NM|0102-4^Hemoglobin A1C^BRLI^4548-4^HEMOGLOBIN A1C/HEMOGLOBIN.TOTAL^LOINC||6.2|%|<5.7|H|||F||83036|201204191358NTE|1|L|GLYCOHEMOGLOBIN A1C AND eAG REFERENCE RANGESNTE|2|L|                         A1C(%)     DIABETES CATEGORY*NTE|3|L|                         <5.7             Normal (non-diabetic)NTE|4|L|                        5.7-6.4           Increased risk of diabetesNTE|5|L|                         =>6.5            Consistent with diabetesNTE|6|L|                         A1C(%)     eAG(ESTIMATED AVERAGE PLASMA GLUCOSE)(mg/dL)NTE|7|L|                          6                 126NTE|8|L|                          7                 154NTE|9|L|                          8                 183NTE|10|L|                          9                 212NTE|11|L|                         10                 240NTE|12|L|                         11                 269NTE|13|L|                         12                 298NTE|14|L|                   *recommended ranges-American Diabetes Association(2010)NTE|15|L|NOTE: Previous reference range 4-6%OBR|3|10389866       |107691769|0151-1^T4 (Thyroxine)||201204180000|201204180000|||||||201204182334||H53870^FARHAT^LAILA^|(718)238-4287|84436||BIOREFERENCE LABORATORIES||201204191358|||F||||OBX|1|NM|0151-1^THYROXINE(T4)^BRLI^3026-2^THYROXINE^LOINC||10.7|ug/dL|4.5-12.0||||F||84436|201204191358OBR|4|10389866       |107691769|0153-7^Thyroid Stimulating Hormone (TSH)||201204180000|201204180000|||||||201204182334||H53870^FARHAT^LAILA^|(718)238-4287|84443||BIOREFERENCE LABORATORIES||201204191358|||F||||OBX|1|NM|0153-7^TSH^BRLI^3016-3^THYROTROPIN^LOINC||2.040|uIU/mL|0.270-4.200||||F||84443|201204191358OBR|5|10389866       |107691769|0157-8^URIC ACID, SERUM||201204180000|201204180000|||||||201204182334||H53870^FARHAT^LAILA^|(718)238-4287|84550||BIOREFERENCE LABORATORIES||201204191358|||F||||OBX|1|NM|0157-8^Uric Acid^BRLI^3084-1^URATE^LOINC||7.3|mg/dL|3.4-7.0|H|||F||84550|201204191358OBR|6|10389866       |107691769|0228-7^MICROALBUMIN, URINE, RANDOM||201204180000|201204180000|||||||201204182334||H53870^FARHAT^LAILA^|(718)238-4287|82042||BIOREFERENCE LABORATORIES||201204191358|||F||||OBX|1|ST|3172-4^MICROALBUMIN,RANDOM^BRLI^14957-5^ALBUMIN^LOINC||<1.2|mg/dL|Not Estab.|N|||F||82043|201204191358OBX|2|NM|1661-8^CREAT.URN.TIMED/RAND^BRLI^35674-1^Creatinine^LOINC||76.0|mg/dL|Not Estab.||||F|||201204191358OBX|3|ST|2699-7^MICROALB/CREAT RATIO^BRLI^14959-1^ALBUMIN/CREATININE^LOINC||Can't Calc|mg/gcreat|<30.0|N|||F||99999|201204191358NTE|1|L|NOTE: New reference range for Microalb/Creat ratio effectiveNTE|2|L|      4/16/12.NTE|3|L|NTE|4|L|Can't Calc: One or more components were not available or was outsideNTE|5|L|            the measurable range. We are unable to calculate.OBR|7|10389866       |107691769|0399-6^CBC W/DIFF, PLATELET CT.||201204180000|201204180000|||||||201204182334||H53870^FARHAT^LAILA^|(718)238-4287|85025||BIOREFERENCE LABORATORIES||201204191358|||F||||OBX|1|NM|1497-7^WBC^BRLI^6690-2^LEUKOCYTES^LOINC||8.37|x10(3)/uL|3.40-11.80||||F||85048|201204191358OBX|2|NM|1498-5^RBC^BRLI^789-8^ERYTHROCYTES^LOINC||5.49|x10(6)/uL|4.20-5.90||||F||85041|201204191358OBX|3|NM|1499-3^HGB^BRLI^718-7^HEMOGLOBIN^LOINC||15.4|gm/dL|12.3-17.0||||F||85018|201204191358OBX|4|NM|0019-0^HCT^BRLI^4544-3^HEMATOCRIT^LOINC||45.2|%|39.3-52.5||||F||85014|201204191358OBX|5|NM|1503-2^MCV^BRLI^787-2^MEAN CORPUSCULAR VOLUME^LOINC||82.3|fL|80.0-100.0||||F|||201204191358OBX|6|NM|1504-0^MCH^BRLI^785-6^ERYTHROCYTE MEAN CORPUSCULAR HEMOGLOBIN^LOINC||28.1|pg|25.0-34.1||||F|||201204191358OBX|7|NM|1502-4^MCHC^BRLI^786-4^ERYTHROCYTE MEAN CORPUSCULAR HEMOGLOBIN CONCENTRAT^LOINC||34.1|gm/dL|29.0-35.0||||F|||201204191358OBX|8|NM|1598-2^RDW^BRLI^788-0^ERYTHROCYTE DISTRIBUTION WIDTH^LOINC||14.0|%|10.9-16.9||||F||85029|201204191358OBX|9|NM|1505-7^POLYS^BRLI^31160-5^POLYMORPHONUCLEAR CELLS/100 LEUKOCYTES^LOINC||62.8|%|36.0-78.0||||F|||201204191358OBX|10|NM|1507-3^LYMPHS^BRLI^736-9^LYMPHOCYTES/100 LEUKOCYTES^LOINC||23.4|%|12.0-48.0||||F|||201204191358OBX|11|NM|1511-5^MONOS^BRLI^51384-6^Mononuclear cells/100 leukocytes^LOINC||7.4|%|0.0-13.0||||F|||201204191358OBX|12|NM|1509-9^EOS^BRLI^713-8^EOSINOPHILS/100 LEUKOCYTES^LOINC||5.4|%|0.0-8.0||||F|||201204191358OBX|13|NM|1510-7^BASOS^BRLI^706-2^BASOPHILS/100 LEUKOCYTES^LOINC||0.5|%|0.0-2.0||||F|||201204191358OBX|14|NM|270053-2^IMMATURE GRANULOCYTES^BRLI^38518-7^GRANULOCYTES.IMMATURE/100 LEUKOCYTES^LOINC||0.5|%|0.0-1.6||||F|||201204191358OBX|15|NM|0128-9^PLATELET COUNT^BRLI^777-3^PLATELETS^LOINC||235|x10(3)/uL|144-400||||F||85595|201204191358OBX|16|NM|400053-5^MPV^BRLI^32623-1^PLATELET MEAN VOLUME^LOINC||10.7|fL|8.2-11.9||||F|||201204191358OBR|8|10389866       |107691769|0459-8^Urinalysis, Routine (w/micros)||201204180000|201204180000|||||||201204182334||H53870^FARHAT^LAILA^|(718)238-4287|81001||BIOREFERENCE LABORATORIES||201204191358|||F||||OBX|1|ST|6315-6^Color^BRLI^5778-6^COLOR^LOINC||YELLOW||YELLOW, STRAW, AMBER|N|||F||99999|201204191358OBX|2|ST|6316-4^Character^BRLI^19244-3^CHARACTER^LOINC||CLEAR||CLEAR|N|||F||99999|201204191358OBX|3|NM|1520-6^Specific Gravity URN^BRLI^2965-2^SPECIFIC GRAVITY^LOINC||1.014||1.003 - 1.030||||F|||201204191358OBX|4|NM|1521-4^pH Urine^BRLI^2756-5^PH^LOINC||6.0||5.0 - 8.0||||F|||201204191358OBX|5|ST|1522-2^Protein, Urine^BRLI^20454-5^PROTEIN^LOINC||NEGATIVE||NEGATIVE|N|||F|||201204191358OBX|6|ST|1523-0^Glucose, Urine^BRLI^25428-4^GLUCOSE^LOINC||NEGATIVE||NEGATIVE|N|||F|||201204191358OBX|7|ST|1524-8^Ketone, Urine^BRLI^2514-8^KETONES^LOINC||NEGATIVE||NEGATIVE|N|||F|||201204191358OBX|8|NM|1525-5^Urobilinogen Urine^BRLI^19161-9^UROBILINOGEN^LOINC||0.2|Units|0.2 - 1.0||||F|||201204191358OBX|9|ST|1526-3^Bilirubin, Urine^BRLI^5770-3^BILIRUBIN^LOINC||NEGATIVE||NEGATIVE|N|||F|||201204191358OBX|10|ST|1527-1^Blood, Urine^BRLI^5794-3^HEMOGLOBIN^LOINC||NEGATIVE||NEGATIVE|N|||F|||201204191358OBX|11|ST|1528-9^Nitrites Urine^BRLI^5802-4^NITRITE^LOINC||NEGATIVE||NEGATIVE|N|||F|||201204191358OBX|12|ST|6311-5^Leukocyte Esterase^BRLI^5799-2^LEUKOCYTE ESTERASE^LOINC||NEGATIVE||NEGATIVE|N|||F||99999|201204191358OBX|13|ST|1529-7^Crystals Urine^BRLI^5782-8^CRYSTALS^LOINC||NONE||NONE|N|||F|||201204191358OBX|14|ST|2135-2^Crystal Amt. Urine^BRLI^5782-8^URINE CRYSTAL AMT.^LOINC||NONE||NONE|N|||F|||201204191358OBX|15|ST|1534-7^WBC, Urine^BRLI^5821-4^LEUKOCYTES^LOINC||0-4|PERHPF|0-4|N|||F|||201204191358OBX|16|ST|1535-4^RBC, Urine^BRLI^13945-1^ERYTHROCYTES^LOINC||NONE SEEN|PERHPF|NONE SEEN|N|||F|||201204191358OBX|17|ST|1546-1^Epithelial Cells, Ur^BRLI^20453-7^EPITHELIAL CELLS^LOINC||NONE||FEW|N|||F|||201204191358NTE|1|L|NTE|2|L|NOTE:  Significant quantities of epithelial cells willNTE|3|L|be identified if they are not squamous cell types.OBX|18|ST|1545-3^Cast, Hyaline, Urine^BRLI^5796-8^HYALINE CASTS^LOINC||0-4|PERLPF|0-4|N|||F|||201204191358OBX|19|ST|1547-9^Cast, Granular, Urin^BRLI^5793-5^GRANULAR CASTS^LOINC||NONE SEEN|PERLPF|0-1|N|||F|||201204191358OBX|20|ST|1543-8^Cast, RBC, Urine^BRLI^5807-3^ERYTHROCYTE CASTS^LOINC||NONE SEEN|PERLPF|0-1|N|||F|||201204191358OBX|21|ST|1549-5^Bacteria, Urine^BRLI^25145-4^BACTERIA^LOINC||NONE||FEW|N|||F|||201204191358OBR|9|10389866       |107691769|3427-2^Comprehensive Metabolic Panel||201204180000|201204180000|||||||201204182334||H53870^FARHAT^LAILA^|(718)238-4287|80099||BIOREFERENCE LABORATORIES||201204191358|||F||||OBX|1|NM|0135-4^Total Protein^BRLI^2885-2^PROTEIN^LOINC||7.5|g/dL|5.9-8.4||||F||84155|201204191358OBX|2|NM|0033-1^Albumin^BRLI^1751-7^ALBUMIN^LOINC||4.3|g/dL|3.5-5.2||||F||82040|201204191358OBX|3|NM|1753-3^Globulin^BRLI^2336-6^GLOBULIN^LOINC||3.2|g/dL|1.7-3.7||||F|||201204191358OBX|4|NM|0641-1^A/G Ratio^BRLI^1759-0^ALBUMIN/GLOBULIN^LOINC||1.3||1.1-2.9||||F|||201204191358OBX|5|NM|0148-7^Sodium^BRLI^2951-2^SODIUM^LOINC||142|mmol/L|133-145||||F||84295|201204191358OBX|6|NM|0129-7^Potassium^BRLI^2823-3^POTASSIUM^LOINC||4.2|mmol/L|3.3-5.3||||F||84132|201204191358OBX|7|NM|0057-0^Chloride^BRLI^2075-0^CHLORIDE^LOINC||103|mmol/L|96-108||||F||82435|201204191358OBX|8|NM|0052-1^CO2^BRLI^2028-9^CARBON DIOXIDE^LOINC||25|mmol/L|22-29||||F||82374|201204191358OBX|9|NM|0049-7^BUN^BRLI^3094-0^UREA NITROGEN^LOINC||10|mg/dL|6-20||||F||84520|201204191358OBX|10|NM|0070-3^Creatinine^BRLI^2160-0^CREATININE^LOINC||0.81|mg/dL|0.90-1.30|L|||F||82565|201204191358NTE|1|L|NOTE: The creatinine reference ranges have changed effective 11/7/11.OBX|11|NM|090013-4^e-GFR^BRLI^^^LOINC||99|mL/min|>60||||F|||201204191358OBX|12|NM|090015-9^e-GFR, African American^BRLI^^^LOINC||120|mL/min|>60||||F|||201204191358OBX|13|NM|1427-4^BUN/Creat Ratio^BRLI^3097-3^UREA NITROGEN/CREATININE^LOINC||12.3||10.0-28.0||||F|||201204191358OBX|14|NM|0050-5^Calcium^BRLI^17861-6^CALCIUM^LOINC||9.8|mg/dL|8.6-10.2||||F||82310|201204191358OBX|15|NM|0043-0^Bilirubin, Total^BRLI^1975-2^BILIRUBIN^LOINC||0.4|mg/dL|0.1-1.0||||F||82247|201204191358OBX|16|NM|0185-9^Alk Phos^BRLI^6768-6^ALKALINE PHOSPHATASE^LOINC||55|U/L|40-129||||F||84075|201204191358OBX|17|NM|0146-1^AST^BRLI^1920-8^ASPARTATE AMINOTRANSFERASE^LOINC||20|U/L|<40||||F||84450|201204191358OBX|18|NM|0147-9^ALT^BRLI^1742-6^ALANINE AMINOTRANSFERASE^LOINC||19|U/L|<41||||F||84460|201204191358OBX|19|NM|1976-0^Glucose^BRLI^2345-7^GLUCOSE^LOINC||105|mg/dL|70-99|H|||F|||201204191358MSH|^~&\|BioRefHMODownload-H|BIO-REFERENCE LABS|02/01/2013 -> 02/01/2013|1200239^|201302011340||ORU^R01|20130201134016.2|P|2.3|1||NE|NEPID|2||107675804|12002556       |ABREU^PEDRO||19570701|F|||3538 95 ST^^JACKSON HEIGHTS^NY^11372||7183058623||||||NTE|1|P|PATIENT FASTINGOBR|1|12002556       |107675804|0080-2^Urine Culture||201204170900|201204170900|||||||201204172357||106429^RAMIREZ, CESAR|(718)334-0001|87086||BIOREFERENCE LABORATORIES||201204210700|||F||||OBX|1|ST|0080-2^CULTURE, URINE^BRLI^630-4^MICROORGANISM IDENTIFIED^LOINC||NO GROWTH||NO GROWTH|N|||F||87086|201204210700NTE|1|L|SOURCE:  UROBR|2|12002556       |107675804|0153-7^Thyroid Stimulating Hormone (TSH)||201204170900|201204170900|||||||201204172357||106429^RAMIREZ, CESAR|(718)334-0001|84443||BIOREFERENCE LABORATORIES||201204210700|||F||||OBX|1|NM|0153-7^TSH^BRLI^3016-3^THYROTROPIN^LOINC||1.650|uIU/mL|0.270-4.200||||F||84443|201204210700OBR|3|12002556       |107675804|0459-8^Urinalysis, Routine (w/micros)||201204170900|201204170900|||||||201204172357||106429^RAMIREZ, CESAR|(718)334-0001|81001||BIOREFERENCE LABORATORIES||201204210700|||F||||OBX|1|ST|6315-6^Color^BRLI^5778-6^COLOR^LOINC||YELLOW||YELLOW, STRAW, AMBER|N|||F||99999|201204210700OBX|2|ST|6316-4^Character^BRLI^19244-3^CHARACTER^LOINC||CLEAR||CLEAR|N|||F||99999|201204210700OBX|3|NM|1520-6^Specific Gravity URN^BRLI^2965-2^SPECIFIC GRAVITY^LOINC||1.020||1.003 - 1.030||||F|||201204210700OBX|4|NM|1521-4^pH Urine^BRLI^2756-5^PH^LOINC||5.0||5.0 - 8.0||||F|||201204210700OBX|5|ST|1522-2^Protein, Urine^BRLI^20454-5^PROTEIN^LOINC||NEGATIVE||NEGATIVE|N|||F|||201204210700OBX|6|ST|1523-0^Glucose, Urine^BRLI^25428-4^GLUCOSE^LOINC||NEGATIVE||NEGATIVE|N|||F|||201204210700OBX|7|ST|1524-8^Ketone, Urine^BRLI^2514-8^KETONES^LOINC||NEGATIVE||NEGATIVE|N|||F|||201204210700OBX|8|NM|1525-5^Urobilinogen Urine^BRLI^19161-9^UROBILINOGEN^LOINC||0.2|Units|0.2 - 1.0||||F|||201204210700OBX|9|ST|1526-3^Bilirubin, Urine^BRLI^5770-3^BILIRUBIN^LOINC||NEGATIVE||NEGATIVE|N|||F|||201204210700OBX|10|ST|1527-1^Blood, Urine^BRLI^5794-3^HEMOGLOBIN^LOINC||NEGATIVE||NEGATIVE|N|||F|||201204210700OBX|11|ST|1528-9^Nitrites Urine^BRLI^5802-4^NITRITE^LOINC||NEGATIVE||NEGATIVE|N|||F|||201204210700OBX|12|ST|6311-5^Leukocyte Esterase^BRLI^5799-2^LEUKOCYTE ESTERASE^LOINC||NEGATIVE||NEGATIVE|N|||F||99999|201204210700OBX|13|ST|1529-7^Crystals Urine^BRLI^5782-8^CRYSTALS^LOINC||NONE||NONE|N|||F|||201204210700OBX|14|ST|2135-2^Crystal Amt. Urine^BRLI^5782-8^URINE CRYSTAL AMT.^LOINC||NONE||NONE|N|||F|||201204210700OBX|15|ST|1534-7^WBC, Urine^BRLI^5821-4^LEUKOCYTES^LOINC||0-4|PERHPF|0-4|N|||F|||201204210700OBX|16|ST|1535-4^RBC, Urine^BRLI^13945-1^ERYTHROCYTES^LOINC||NONE SEEN|PERHPF|NONE SEEN|N|||F|||201204210700OBX|17|ST|1546-1^Epithelial Cells, Ur^BRLI^20453-7^EPITHELIAL CELLS^LOINC||FEW||FEW|N|||F|||201204210700NTE|1|L|NTE|2|L|NOTE:  Significant quantities of epithelial cells willNTE|3|L|be identified if they are not squamous cell types.OBX|18|ST|1545-3^Cast, Hyaline, Urine^BRLI^5796-8^HYALINE CASTS^LOINC||0-4|PERLPF|0-4|N|||F|||201204210700OBX|19|ST|1547-9^Cast, Granular, Urin^BRLI^5793-5^GRANULAR CASTS^LOINC||NONE SEEN|PERLPF|0-1|N|||F|||201204210700OBX|20|ST|1543-8^Cast, RBC, Urine^BRLI^5807-3^ERYTHROCYTE CASTS^LOINC||NONE SEEN|PERLPF|0-1|N|||F|||201204210700OBX|21|ST|1549-5^Bacteria, Urine^BRLI^25145-4^BACTERIA^LOINC||NONE||FEW|N|||F|||201204210700OBR|4|12002556       |107675804|9761-8^ACT 3 (ACT 1 and ChemProfile 24 and CBC)||201204170900|201204170900|||||||201204172357||106429^RAMIREZ, CESAR|(718)334-0001|80099||BIOREFERENCE LABORATORIES||201204210700|||F||||OBX|1|NM|0135-4^Total Protein^BRLI^2885-2^PROTEIN^LOINC||7.4|g/dL|5.9-8.4||||F||84155|201204210700OBX|2|NM|0033-1^Albumin^BRLI^1751-7^ALBUMIN^LOINC||4.8|g/dL|3.5-5.2||||F||82040|201204210700OBX|3|NM|1753-3^Globulin^BRLI^2336-6^GLOBULIN^LOINC||2.6|g/dL|1.7-3.7||||F|||201204210700OBX|4|NM|0641-1^A/G Ratio^BRLI^1759-0^ALBUMIN/GLOBULIN^LOINC||1.8||1.1-2.9||||F|||201204210700OBX|5|NM|1976-0^Glucose^BRLI^2345-7^GLUCOSE^LOINC||99|mg/dL|70-99||||F|||201204210700OBX|6|NM|0148-7^Sodium^BRLI^2951-2^SODIUM^LOINC||141|mmol/L|133-145||||F||84295|201204210700OBX|7|NM|0129-7^Potassium^BRLI^2823-3^POTASSIUM^LOINC||5.0|mmol/L|3.3-5.3||||F||84132|201204210700OBX|8|NM|0057-0^Chloride^BRLI^2075-0^CHLORIDE^LOINC||100|mmol/L|96-108||||F||82435|201204210700OBX|9|NM|0052-1^CO2^BRLI^2028-9^CARBON DIOXIDE^LOINC||29|mmol/L|22-29||||F||82374|201204210700OBX|10|NM|0049-7^BUN^BRLI^3094-0^UREA NITROGEN^LOINC||18|mg/dL|6-20||||F||84520|201204210700OBX|11|NM|0070-3^Creatinine^BRLI^2160-0^CREATININE^LOINC||1.41|mg/dL|0.60-1.10|H|||F||82565|201204210700NTE|1|L|NOTE: The creatinine reference ranges have changed effective 11/7/11.OBX|12|NM|090013-4^e-GFR^BRLI^^^LOINC||39|mL/min|>60|L|||F|||201204210700OBX|13|NM|090015-9^e-GFR, African American^BRLI^^^LOINC||47|mL/min|>60|L|||F|||201204210700OBX|14|NM|1427-4^BUN/Creat Ratio^BRLI^3097-3^UREA NITROGEN/CREATININE^LOINC||12.8||10.0-28.0||||F|||201204210700OBX|15|NM|0050-5^Calcium^BRLI^17861-6^CALCIUM^LOINC||9.4|mg/dL|8.6-10.2||||F||82310|201204210700OBX|16|NM|0157-8^Uric Acid^BRLI^3084-1^URATE^LOINC||7.6|mg/dL|2.4-5.7|H|||F||84550|201204210700OBX|17|NM|0114-9^Iron^BRLI^2498-4^IRON^LOINC||100|ug/dL|30-160||||F||83540|201204210700OBX|18|NM|0043-0^Bilirubin, Total^BRLI^1975-2^BILIRUBIN^LOINC||0.3|mg/dL|0.1-1.0||||F||82247|201204210700OBX|19|NM|0117-2^LD^BRLI^2532-0^LACTATE DEHYDROGENASE^LOINC||154|U/L|135-214||||F||83615|201204210700OBX|20|NM|0185-9^Alk Phos^BRLI^6768-6^ALKALINE PHOSPHATASE^LOINC||48|U/L|35-104||||F||84075|201204210700OBX|21|NM|0146-1^AST^BRLI^1920-8^ASPARTATE AMINOTRANSFERASE^LOINC||24|U/L|<32||||F||84450|201204210700OBX|22|NM|0127-1^Phosphorus^BRLI^2777-1^PHOSPHATE^LOINC||4.0|mg/dL|2.7-4.5||||F||84100|201204210700OBX|23|NM|0147-9^ALT^BRLI^1742-6^ALANINE AMINOTRANSFERASE^LOINC||21|U/L|<33||||F||84460|201204210700OBX|24|NM|0093-5^GGTP^BRLI^2324-2^GAMMA GLUTAMYL TRANSFERASE^LOINC||9|U/L|6-42||||F||82977|201204210700OBX|25|NM|0058-8^Cholesterol^BRLI^2093-3^CHOLESTEROL^LOINC||126|mg/dL|<200||||F||82465|201204210700OBX|26|NM|0155-2^Triglycerides^BRLI^2571-8^TRIGLYCERIDE^LOINC||118|mg/dL|<150||||F||84478|201204210700OBX|27|NM|0059-6^HDL CHOL., DIRECT^BRLI^2085-9^CHOLESTEROL.IN HDL^LOINC||44||>50|L|||F||83718|201204210700OBX|28|NM|1421-7^Chol/HDL Ratio^BRLI^9830-1^CHOLESTEROL.TOTAL/CHOLESTEROL.IN HDL^LOINC||2.9||<5.8||||F|||201204210700NTE|1|L|Evaluation: BELOW AVERAGE RISKOBX|29|NM|1764-0^HDL as % of Cholesterol^BRLI^2095-8^CHOLESTEROL.IN HDL/CHOLESTEROL.TOTAL^LOINC||35|%|>14||||F|||201204210700NTE|1|L|Evaluation: BELOW AVERAGE RISKOBX|30|NM|0253-5^LDL/HDL Ratio^BRLI^11054-4^CHOLESTEROL.IN LDL/CHOLESTEROL.IN HDL^LOINC||1.32||<3.56||||F|||201204210700OBX|31|NM|0505-8^LDL Cholesterol^BRLI^2089-1^CHOLESTEROL.IN LDL^LOINC||58|mg/dL|<100||||F||83720|201204210700OBX|32|NM|3345-6^VLDL, CALCULATED^BRLI^^^LOINC||24|mg/dL|7-32||||F||99999|201204210700OBX|33|NM|6244-8^LDL-P TOTAL CT. (29)^BRLI^^^LOINC||778|nmol/L|<1000||||F||83704|201204210700NTE|1|L|(29) NTE|2|L|LDL Particle Testing Performed at: LiposcienceNTE|3|L|                                   2500 Sumner BlvdNTE|4|L|                                   Raleigh, NC 27616OBX|34|NM|6245-5^SMALL LDL-P (29)^BRLI^43727-7^LIPOPROTEIN.BETA.SUBPARTICLE.SMALL^LOINC||318|nmol/L|<117|H|||F||83704|201204210700NTE|1|L|(29) NTE|2|L|LDL Particle Testing Performed at: LiposcienceNTE|3|L|                                   2500 Sumner BlvdNTE|4|L|                                   Raleigh, NC 27616OBX|35|NM|6243-0^LDL PARTICLE SIZE (29)^BRLI^17782-4^^LOINC||21.1|nm|>20.5||||F||83704|201204210700NTE|1|L|(29) NTE|2|L|LDL Particle Testing Performed at: LiposcienceNTE|3|L|                                   2500 Sumner BlvdNTE|4|L|                                   Raleigh, NC 27616OBX|36|NM|A125-7^HDL PARTICLE COUNT (29)^BRLI^^^LOINC||25.9|umol/L|>40.0|L|||F||99999|201204210700NTE|1|L|Small LDL-P, LDL Particle Size, and Large HDL-P have been validated byNTE|2|L|LipoScience but not cleared by US FDA; the clinical utility of theseNTE|3|L|test results has not been fully established.NTE|4|L|(29) NTE|5|L|LDL Particle Testing Performed at: LiposcienceNTE|6|L|                                   2500 Sumner BlvdNTE|7|L|                                   Raleigh, NC 27616OBX|37|NM|6288-5^HDL-P LARGE (29)^BRLI^43729-3^Lipoprotein.alpha.subparticle.large^LOINC||3.6|umol/L|>9.0|L|||F||99999|201204210700NTE|1|L|(29) NTE|2|L|LDL Particle Testing Performed at: LiposcienceNTE|3|L|                                   2500 Sumner BlvdNTE|4|L|                                   Raleigh, NC 27616OBX|38|NM|0457-2^APOLIPOPROTEIN B^BRLI^1884-6^APOLIPOPROTEIN B^LOINC||53|mg/dL|60-117|L|||F||82172|201204210700OBX|39|NM|1497-7^WBC^BRLI^6690-2^LEUKOCYTES^LOINC||5.57|x10(3)/uL|3.40-11.80||||F||85048|201204210700OBX|40|NM|1498-5^RBC^BRLI^789-8^ERYTHROCYTES^LOINC||4.22|x10(6)/uL|3.60-5.50||||F||85041|201204210700OBX|41|NM|1499-3^HGB^BRLI^718-7^HEMOGLOBIN^LOINC||12.4|gm/dL|11.5-15.6||||F||85018|201204210700OBX|42|NM|0019-0^HCT^BRLI^4544-3^HEMATOCRIT^LOINC||37.7|%|34.5-46.5||||F||85014|201204210700OBX|43|NM|1503-2^MCV^BRLI^787-2^MEAN CORPUSCULAR VOLUME^LOINC||89.3|fL|80.0-100.0||||F|||201204210700OBX|44|NM|1504-0^MCH^BRLI^785-6^ERYTHROCYTE MEAN CORPUSCULAR HEMOGLOBIN^LOINC||29.4|pg|25.0-34.1||||F|||201204210700OBX|45|NM|1502-4^MCHC^BRLI^786-4^ERYTHROCYTE MEAN CORPUSCULAR HEMOGLOBIN CONCENTRAT^LOINC||32.9|gm/dL|29.0-35.0||||F|||201204210700OBX|46|NM|1598-2^RDW^BRLI^788-0^ERYTHROCYTE DISTRIBUTION WIDTH^LOINC||15.3|%|10.9-16.9||||F||85029|201204210700OBX|47|NM|1505-7^POLYS^BRLI^31160-5^POLYMORPHONUCLEAR CELLS/100 LEUKOCYTES^LOINC||53.5|%|36.0-78.0||||F|||201204210700OBX|48|NM|1507-3^LYMPHS^BRLI^736-9^LYMPHOCYTES/100 LEUKOCYTES^LOINC||33.9|%|12.0-48.0||||F|||201204210700OBX|49|NM|1511-5^MONOS^BRLI^51384-6^Mononuclear cells/100 leukocytes^LOINC||10.4|%|0.0-13.0||||F|||201204210700OBX|50|NM|1509-9^EOS^BRLI^713-8^EOSINOPHILS/100 LEUKOCYTES^LOINC||1.6|%|0.0-8.0||||F|||201204210700OBX|51|NM|1510-7^BASOS^BRLI^706-2^BASOPHILS/100 LEUKOCYTES^LOINC||0.4|%|0.0-2.0||||F|||201204210700OBX|52|NM|270053-2^IMMATURE GRANULOCYTES^BRLI^38518-7^GRANULOCYTES.IMMATURE/100 LEUKOCYTES^LOINC||0.2|%|0.0-1.6||||F|||201204210700OBX|53|NM|0128-9^PLATELET COUNT^BRLI^777-3^PLATELETS^LOINC||265|x10(3)/uL|144-400||||F||85595|201204210700OBX|54|NM|400053-5^MPV^BRLI^32623-1^PLATELET MEAN VOLUME^LOINC||10.3|fL|8.2-11.9||||F|||201204210700MSH|^~&\|BioRefHMODownload-H|BIO-REFERENCE LABS|02/01/2013 -> 02/01/2013|1200239^|201302011340||ORU^R01|20130201134016.3|P|2.3|1||NE|NEPID|3||100478347|12002556       |ABREU^PEDRO||19570701|M|||3538 95TH ST^^JACKSON HEIGHTS^NY^11372|||||||||||UNTE|1|P|PATIENT FASTINGOBR|1|12002556       |100478347|0080-2^Urine Culture||201210091300|201210091300|||||||201210092329||106429^RAMIREZ, CESAR|(718)334-0001|87086||BIOREFERENCE LABORATORIES||201210111211|||F||||OBX|1|ST|0080-2^CULTURE, URINE^BRLI^630-4^MICROORGANISM IDENTIFIED^LOINC||NO GROWTH||NO GROWTH|N|||F||87086|201210111211OBR|2|12002556       |100478347|0091-9^THYROXINE, FREE (FT4)||201210091300|201210091300|||||||201210092329||106429^RAMIREZ, CESAR|(718)334-0001|84439||BIOREFERENCE LABORATORIES||201210111211|||F||||OBX|1|NM|0091-9^THYROXINE, FREE (FT4)^BRLI^3024-7^THYROXINE.FREE^LOINC||1.42|ng/dL|0.83-1.62||||F||84439|201210111211OBR|3|12002556       |100478347|0102-4^Hemoglobin A1C (Glycohgb)||201210091300|201210091300|||||||201210092329||106429^RAMIREZ, CESAR|(718)334-0001|83036||BIOREFERENCE LABORATORIES||201210111211|||F||||OBX|1|NM|0102-4^Hemoglobin A1C^BRLI^4548-4^HEMOGLOBIN A1C/HEMOGLOBIN.TOTAL^LOINC||6.3|%|<5.7|H|||F||83036|201210111211NTE|1|L|GLYCOHEMOGLOBIN A1C AND eAG REFERENCE RANGESNTE|2|L|                         A1C(%)     DIABETES CATEGORY*NTE|3|L|                         <5.7             Normal (non-diabetic)NTE|4|L|                        5.7-6.4           Increased risk of diabetesNTE|5|L|                         =>6.5            Consistent with diabetesNTE|6|L|                         A1C(%)     eAG(ESTIMATED AVERAGE PLASMA GLUCOSE)(mg/dL)NTE|7|L|                          6                 126NTE|8|L|                          7                 154NTE|9|L|                          8                 183NTE|10|L|                          9                 212NTE|11|L|                         10                 240NTE|12|L|                         11                 269NTE|13|L|                         12                 298NTE|14|L|                   *recommended ranges-American Diabetes Association(2010)NTE|15|L|NOTE: Previous reference range 4-6%OBR|4|12002556       |100478347|0137-0^PROTHROMBIN TIME/INR (PT)||201210091300|201210091300|||||||201210092329||106429^RAMIREZ, CESAR|(718)334-0001|85610||BIOREFERENCE LABORATORIES||201210111211|||F||||OBX|1|ST|0137-0^PROTIME^BRLI^5902-2^PT;PROTHROMBIN TIME;PROTIME^LOINC||TNP|||N|||F||85610|201210111211NTE|1|L|TEST NOT PERFORMED; LIGHT BLUE TOP NOT RECEIVED.OBR|5|12002556       |100478347|0139-6^PTT (PARTIAL THROMBOPLASTIN TIME)||201210091300|201210091300|||||||201210092329||106429^RAMIREZ, CESAR|(718)334-0001|85730||BIOREFERENCE LABORATORIES||201210111211|||F||||OBX|1|ST|0139-6^PTT^BRLI^14979-9^COAGULATION SURFACE INDUCED^LOINC||TNP|||N|||F||85730|201210111211NTE|1|L|TEST NOT PERFORMED; LIGHT BLUE TOP NOT RECEIVED.OBR|6|12002556       |100478347|0142-0^RPR SEROLOGY||201210091300|201210091300|||||||201210092329||106429^RAMIREZ, CESAR|(718)334-0001|86592||BIOREFERENCE LABORATORIES||201210111211|||F||||OBX|1|ST|0142-0^RPR^BRLI^11084-1^REAGIN AB^LOINC||Non-Reactive|Titer|Non-Reactive|N|||F||86592|201210111211OBR|7|12002556       |100478347|0150-3^T3, Total||201210091300|201210091300|||||||201210092329||106429^RAMIREZ, CESAR|(718)334-0001|84480||BIOREFERENCE LABORATORIES||201210111211|||F||||OBX|1|NM|0150-3^T3 (THYRONINE), TOTAL^BRLI^3053-6^TRIIODOTHYRONINE^LOINC||100|ng/dL|80-200||||F||84480|201210111211OBR|8|12002556       |100478347|0153-7^Thyroid Stimulating Hormone (TSH)||201210091300|201210091300|||||||201210092329||106429^RAMIREZ, CESAR|(718)334-0001|84443||BIOREFERENCE LABORATORIES||201210111211|||F||||OBX|1|NM|0153-7^TSH^BRLI^3016-3^THYROTROPIN^LOINC||2.660|uIU/mL|0.270-4.200||||F||84443|201210111211OBR|9|12002556       |100478347|0228-7^MICROALBUMIN, URINE, RANDOM||201210091300|201210091300|||||||201210092329||106429^RAMIREZ, CESAR|(718)334-0001|82042||BIOREFERENCE LABORATORIES||201210111211|||F||||OBX|1|ST|3172-4^MICROALBUMIN,RANDOM^BRLI^14957-5^ALBUMIN^LOINC||<1.2|mg/dL|Not Estab.|N|||F||82043|201210111211OBX|2|NM|1661-8^CREAT.URN.TIMED/RAND^BRLI^35674-1^Creatinine^LOINC||54.9|mg/dL|Not Estab.||||F||82570,80002|201210111211OBX|3|ST|2699-7^MICROALB/CREAT RATIO^BRLI^14959-1^ALBUMIN/CREATININE^LOINC||Can't Calc|mg/gcreat|<30.0|N|||F||99999|201210111211NTE|1|L|NOTE: New reference range for Microalb/Creat ratio effectiveNTE|2|L|      4/16/12.NTE|3|L|NTE|4|L|Can't Calc: One or more components were not available or was outsideNTE|5|L|            the measurable range. We are unable to calculate.OBR|10|12002556       |100478347|0286-5^Vitamin D, 25-Hydroxy, Serum||201210091300|201210091300|||||||201210092329||106429^RAMIREZ, CESAR|(718)334-0001|82307||BIOREFERENCE LABORATORIES||201210111211|||F||||OBX|1|NM|0286-5^25OH, VITAMIN D^BRLI^62292-8^CALCIDIOL^LOINC||31.0|ng/mL|32.0-100.0|L|||F||82307|201210111211OBR|11|12002556       |100478347|0287-3^VIT B12/FOLATE||201210091300|201210091300|||||||201210092329||106429^RAMIREZ, CESAR|(718)334-0001|80099||BIOREFERENCE LABORATORIES||201210111211|||F||||OBX|1|NM|0090-1^FOLIC ACID^BRLI^2284-8^FOLATE^LOINC||12.08|ng/mL|>5.38||||F||82746|201210111211NTE|1|L|Folic Acid RangeNTE|2|L|                                         Units (ng/mL)NTE|3|L|             Normal                         >5.38NTE|4|L|             Borderline deficient         3.38-5.38NTE|5|L|             Deficient                    0.35-3.37NTE|6|L|             Excessive                     >24.00OBX|2|NM|0160-2^VITAMIN B12^BRLI^2132-9^COBALAMINS^LOINC||371|pg/mL|211-911||||F||82607|201210111211OBR|12|12002556       |100478347|0293-1^VITAMIN B1, FREE THIAMINE||201210091300|201210091300|||||||201210092329||106429^RAMIREZ, CESAR|(718)334-0001|84425||BIOREFERENCE LABORATORIES||201210111211|||F||||OBX|1|NM|0293-1^VITB1,THIAMINE,FREE^BRLI^49115-9^THIAMINE.FREE^LOINC||7.9|ng/mL|2.7-13.3||||F||84425|201210111211NTE|1|L|* Please note that specimens submitted for Vitamins B1, B2, B6 andNTE|2|L|  C should be submitted FROZEN. Unfrozen specimens may produce NTE|3|L|  lower results.NTE|4|L|NOTE: The following vitamins and minerals: VITAMIN A, B1, B2, B6, NTE|5|L|      C, E, BETA CAROTENE, ALUMINUM, MAGNESIUM, and ZINC were NTE|6|L|      evaluated and their performance characteristics determinedNTE|7|L|      by BioReference Laboratories. They have not been cleared NTE|8|L|      or approved by the U.S. Food and Drug Administration. The NTE|9|L|      FDA has determined that such a clearance or approval is notNTE|10|L|      necessary. The results reported for these procedures areNTE|11|L|      for research use only. BioReference Laboratories is cert-NTE|12|L|      ified under the Clinical Laboratory Improvement Act of 1988NTE|13|L|      (CLIA) as qualified to perform high-complexity clinicalNTE|14|L|      testing.OBR|13|12002556       |100478347|0360-8^HIV 1/2 Antibody||201210091300|201210091300|||||||201210092329||106429^RAMIREZ, CESAR|(718)334-0001|86312||BIOREFERENCE LABORATORIES||201210111211|||F||||OBX|1|ST|0360-8^HIV 1/2 ANTIBODY^BRLI^31201-7^HIV 1+O+2 AB^LOINC||Negative||Negative|N|||F||86312|201210111211NTE|1|L|NOTE: Patients negative for HIV antibody MAY BE infected but have not yetNTE|2|L|      seroconverted. If a negative result seems inconsistent with theNTE|3|L|      clinical setting, RESUBMIT a new specimen for retest in 1-3 months.NTE|4|L|ASSAY INFORMATION: Assay for the Detection of Antibodies to HumanNTE|5|L|                   Immunodeficiency Virus Type 1,(HIV-1) and/or Type 2 (HIV-2).NTE|6|L|                   Method: Chemiluminescence (Ortho Clinical Diagnostics)OBR|14|12002556       |100478347|0459-8^Urinalysis, Routine (w/micros)||201210091300|201210091300|||||||201210092329||106429^RAMIREZ, CESAR|(718)334-0001|81001||BIOREFERENCE LABORATORIES||201210111211|||F||||OBX|1|ST|6315-6^Color^BRLI^5778-6^COLOR^LOINC||YELLOW||YELLOW, STRAW, AMBER|N|||F||99999|201210111211OBX|2|ST|6316-4^Character^BRLI^19244-3^CHARACTER^LOINC||CLEAR||CLEAR|N|||F||99999|201210111211OBX|3|NM|1520-6^Specific Gravity URN^BRLI^2965-2^SPECIFIC GRAVITY^LOINC||1.007||1.003 - 1.030||||F||81001.03|201210111211OBX|4|NM|1521-4^pH Urine^BRLI^2756-5^PH^LOINC||5.0||5.0 - 8.0||||F||81001.04|201210111211OBX|5|ST|1522-2^Protein, Urine^BRLI^20454-5^PROTEIN^LOINC||NEGATIVE||NEGATIVE|N|||F||81001.05|201210111211OBX|6|ST|1523-0^Glucose, Urine^BRLI^25428-4^GLUCOSE^LOINC||NEGATIVE||NEGATIVE|N|||F||81001.06|201210111211OBX|7|ST|1524-8^Ketone, Urine^BRLI^2514-8^KETONES^LOINC||NEGATIVE||NEGATIVE|N|||F||81001.07|201210111211OBX|8|NM|1525-5^Urobilinogen Urine^BRLI^19161-9^UROBILINOGEN^LOINC||0.2|Units|0.2 - 1.0||||F||81001.08|201210111211OBX|9|ST|1526-3^Bilirubin, Urine^BRLI^5770-3^BILIRUBIN^LOINC||NEGATIVE||NEGATIVE|N|||F||81001.09|201210111211OBX|10|ST|1527-1^Blood, Urine^BRLI^5794-3^HEMOGLOBIN^LOINC||NEGATIVE||NEGATIVE|N|||F||81001.1|201210111211OBX|11|ST|1528-9^Nitrites Urine^BRLI^5802-4^NITRITE^LOINC||NEGATIVE||NEGATIVE|N|||F||81001.11|201210111211OBX|12|ST|6311-5^Leukocyte Esterase^BRLI^5799-2^LEUKOCYTE ESTERASE^LOINC||NEGATIVE||NEGATIVE|N|||F||99999|201210111211OBX|13|ST|1529-7^Crystals Urine^BRLI^5782-8^CRYSTALS^LOINC||NONE||NONE|N|||F||81001.12|201210111211OBX|14|ST|2135-2^Crystal Amt. Urine^BRLI^5782-8^URINE CRYSTAL AMT.^LOINC||NONE||NONE|N|||F||81000.34|201210111211OBX|15|ST|1534-7^WBC, Urine^BRLI^5821-4^LEUKOCYTES^LOINC||0-4|PERHPF|0-4|N|||F||81001.17|201210111211OBX|16|ST|1535-4^RBC, Urine^BRLI^13945-1^ERYTHROCYTES^LOINC||NONE SEEN|PERHPF|NONE SEEN|N|||F||81001.18|201210111211OBX|17|ST|1546-1^Epithelial Cells, Ur^BRLI^20453-7^EPITHELIAL CELLS^LOINC||NONE||FEW|N|||F||81001.28|201210111211NTE|1|L|NTE|2|L|NOTE:  Significant quantities of epithelial cells willNTE|3|L|be identified if they are not squamous cell types.OBX|18|ST|1545-3^Cast, Hyaline, Urine^BRLI^5796-8^HYALINE CASTS^LOINC||0-4|PERLPF|0-4|N|||F||81001.27|201210111211OBX|19|ST|1547-9^Cast, Granular, Urin^BRLI^5793-5^GRANULAR CASTS^LOINC||NONE SEEN|PERLPF|0-1|N|||F||81001.29|201210111211OBX|20|ST|1543-8^Cast, RBC, Urine^BRLI^5807-3^ERYTHROCYTE CASTS^LOINC||NONE SEEN|PERLPF|0-1|N|||F||81001.25|201210111211OBX|21|ST|1549-5^Bacteria, Urine^BRLI^25145-4^BACTERIA^LOINC||NONE||FEW|N|||F||81001.31|201210111211OBR|15|12002556       |100478347|0538-9^HEPATITIS A AB, IgM||201210091300|201210091300|||||||201210092329||106429^RAMIREZ, CESAR|(718)334-0001|86709||BIOREFERENCE LABORATORIES||201210111211|||F||||OBX|1|ST|0538-9^HEPATITIS A Ab,IgM^BRLI^5182-1^HEPATITIS A VIRUS AB.IGM^LOINC||Negative||Negative|N|||F||86709|201210111211NTE|1|L|NOTE: Hep A Ab,IgM is positive during the acute phase. Hep A Ab/Total is positiveNTE|2|L|      during the recovery phase or is indicative of a past infection.OBR|16|12002556       |100478347|0570-2^HERPES II AB., IgG||201210091300|201210091300|||||||201210092329||106429^RAMIREZ, CESAR|(718)334-0001|86171||BIOREFERENCE LABORATORIES||201210111211|||F||||OBX|1|ST|0570-2^HERPES II Ab.(IgG)^BRLI^7912-9^HERPES SIMPLEX VIRUS 2 AB.IGG^LOINC||<0.2|AI|<0.9|N|||F||86171|201210111211NTE|1|L|INTERPRETATION OF RESULTS FOR HSV-1 AND HSV-2 IgG ANTIBODYNTE|2|L|       Antibody Index    Result            InterpretationNTE|3|L|            <0.9 AI     Negative     No HSV-IgG antibody detectedNTE|4|L|         0.9-1.0 AI     Equivocal    Equivocal result. Repeat in 4-6 weeksNTE|5|L|         >or=1.1 AI     Positive     IgG antibody detectedNTE|6|L|***Comment:This assay is type specific and will differentiate between Herpes Simplex 1 and 2NTE|7|L|           infections. Test results should be interpreted in conjunction with clinical history.NTE|8|L|           The performance of this assay has not been established for pediatric populations, forNTE|9|L|           neonatal screening or for testing the immunocompromised.NTE|10|L|NOTE:New methodology and reference range effective 4/4/12.OBR|17|12002556       |100478347|0598-3^PTH, INTACT (use 1689)||201210091300|201210091300|||||||201210092329||106429^RAMIREZ, CESAR|(718)334-0001|83970||BIOREFERENCE LABORATORIES||201210111211|||F||||OBX|1|NM|0598-3^PTH, INTACT^BRLI^2731-8^PARATHYRIN.INTACT^LOINC||44.6|pg/mL|14.0-72.0||||F||83970|201210111211OBX|2|NM|0050-5^Calcium^BRLI^17861-6^CALCIUM^LOINC||9.7|mg/dL|8.6-10.2||||F||82310|201210111211OBR|18|12002556       |100478347|0812-8^HEPATITIS C ANTIBODY, EIA||201210091300|201210091300|||||||201210092329||106429^RAMIREZ, CESAR|(718)334-0001|86803||BIOREFERENCE LABORATORIES||201210111211|||F||||OBX|1|ST|0812-8^HEPATITIS C Ab.^BRLI^13955-0^HEPATITIS C VIRUS AB^LOINC||Negative||Negative|N|||F||86803|201210111211OBR|19|12002556       |100478347|0992-8^HEPATITIS/COMPREHENSIVE||201210091300|201210091300|||||||201210092329||106429^RAMIREZ, CESAR|(718)334-0001|80099||BIOREFERENCE LABORATORIES||201210111211|||F||||OBX|1|ST|0538-9^HEPATITIS A Ab,IgM^BRLI^5182-1^HEPATITIS A VIRUS AB.IGM^LOINC||Negative||Negative|N|||F||86709|201210111211NTE|1|L|NOTE: Hep A Ab,IgM is positive during the acute phase. Hep A Ab/Total is positiveNTE|2|L|      during the recovery phase or is indicative of a past infection.OBX|2|ST|0105-7^HEPATITIS A Ab/TOTAL^BRLI^53776-1^HEPATITIS A VIRUS AB.IGM + TOTAL^LOINC||Positive||Negative|A|||F||86708.04|201210111211OBX|3|ST|0106-5^HBsAg^BRLI^5195-3^HEPATITIS B VIRUS SURFACE AG^LOINC||Negative||Negative|N|||F||87340|201210111211OBX|4|ST|0107-3^HBsAb^BRLI^22322-2^HEPATITIS B VIRUS SURFACE AB^LOINC||Positive||Negative|A|||F||86706|201210111211NTE|1|L|NOTE: A positive HBsAb result indicates exposure to Hepatitis B virusNTE|2|L|      due to an active infection or inoculation. Hepatitis B antibodies whichNTE|3|L|      are 12 mIU/mL or greater are considered adequate for immunity toNTE|4|L|      infection (use test # 1606, HBsAb Quant).OBX|5|ST|0108-1^HEP.B.CORE AB.^BRLI^16933-4^HEPATITIS B VIRUS CORE AB^LOINC||Positive||Negative|A|||F||86704|201210111211OBX|6|ST|0539-7^HBeAg^BRLI^13954-3^HEPATITIS B VIRUS LITTLE E AG^LOINC||Negative||Negative|N|||F||86293|201210111211OBX|7|ST|0540-5^HBeAb^BRLI^22320-6^HEPATITIS B VIRUS LITTLE E AB^LOINC||Negative||Negative|N|||F||86295|201210111211OBR|20|12002556       |100478347|3320-9^C-Reactive Protein High Sensitivity||201210091300|201210091300|||||||201210092329||106429^RAMIREZ, CESAR|(718)334-0001|86140||BIOREFERENCE LABORATORIES||201210111211|||F||||OBX|1|NM|3320-9^hsCRP^BRLI^30522-7^C REACTIVE PROTEIN^LOINC||0.7|mg/L|See Below||||F||86140|201210111211NTE|1|L|HIGH SENSITIVITY CRP (hsCRP) (test#3320) REFERENCE RANGESNTE|2|L|                      Range (mg/L)     Relative Risk of Future MI or StrokeNTE|3|L|                         <1.0                  LOWNTE|4|L|                        1.0-3.0                AVERAGENTE|5|L|                          >3.0                 HIGHOBR|21|12002556       |100478347|9761-8^ACT 3 (ACT 1 and ChemProfile 24 and CBC)||201210091300|201210091300|||||||201210092329||106429^RAMIREZ, CESAR|(718)334-0001|80099||BIOREFERENCE LABORATORIES||201210111211|||F||||OBX|1|NM|0135-4^Total Protein^BRLI^2885-2^PROTEIN^LOINC||7.0|g/dL|5.9-8.4||||F||84155|201210111211OBX|2|NM|0033-1^Albumin^BRLI^1751-7^ALBUMIN^LOINC||4.7|g/dL|3.5-5.2||||F||82040|201210111211OBX|3|NM|1753-3^Globulin^BRLI^2336-6^GLOBULIN^LOINC||2.3|g/dL|1.7-3.7||||F||G0059.02|201210111211OBX|4|NM|0641-1^A/G Ratio^BRLI^1759-0^ALBUMIN/GLOBULIN^LOINC||2.0||1.1-2.9||||F||G0059.04|201210111211OBX|5|NM|1976-0^Glucose^BRLI^2345-7^GLUCOSE^LOINC||152|mg/dL|70-99|H|||F||82947.01|201210111211OBX|6|NM|0148-7^Sodium^BRLI^2951-2^SODIUM^LOINC||139|mmol/L|133-145||||F||84295|201210111211OBX|7|NM|0129-7^Potassium^BRLI^2823-3^POTASSIUM^LOINC||4.8|mmol/L|3.3-5.3||||F||84132|201210111211OBX|8|NM|0057-0^Chloride^BRLI^2075-0^CHLORIDE^LOINC||99|mmol/L|96-108||||F||82435|201210111211OBX|9|NM|0052-1^CO2^BRLI^2028-9^CARBON DIOXIDE^LOINC||25|mmol/L|22-29||||F||82374|201210111211OBX|10|NM|0049-7^BUN^BRLI^3094-0^UREA NITROGEN^LOINC||13|mg/dL|6-20||||F||84520|201210111211OBX|11|NM|0070-3^Creatinine^BRLI^2160-0^CREATININE^LOINC||1.10|mg/dL|0.90-1.30||||F||82565|201210111211OBX|12|NM|090013-4^e-GFR^BRLI^^^LOINC||69|mL/min|>60||||F|||201210111211OBX|13|NM|090015-9^e-GFR, African American^BRLI^^^LOINC||83|mL/min|>60||||F|||201210111211OBX|14|NM|1427-4^BUN/Creat Ratio^BRLI^3097-3^UREA NITROGEN/CREATININE^LOINC||11.8||10.0-28.0||||F||G0059.01|201210111211OBX|15|NM|0050-5^Calcium^BRLI^17861-6^CALCIUM^LOINC||9.7|mg/dL|8.6-10.2||||F||82310|201210111211OBX|16|NM|0157-8^Uric Acid^BRLI^3084-1^URATE^LOINC||7.1|mg/dL|3.4-7.0|H|||F||84550|201210111211OBX|17|NM|0114-9^Iron^BRLI^2498-4^IRON^LOINC||57|ug/dL|45-160||||F||83540|201210111211OBX|18|NM|0043-0^Bilirubin, Total^BRLI^1975-2^BILIRUBIN^LOINC||0.3|mg/dL|0.1-1.0||||F||82247|201210111211OBX|19|NM|0117-2^LD^BRLI^2532-0^LACTATE DEHYDROGENASE^LOINC||135|U/L|135-225||||F||83615|201210111211OBX|20|NM|0185-9^Alk Phos^BRLI^6768-6^ALKALINE PHOSPHATASE^LOINC||47|U/L|40-129||||F||84075|201210111211OBX|21|NM|0146-1^AST^BRLI^1920-8^ASPARTATE AMINOTRANSFERASE^LOINC||15|U/L|<40||||F||84450|201210111211OBX|22|NM|0127-1^Phosphorus^BRLI^2777-1^PHOSPHATE^LOINC||2.6|mg/dL|2.7-4.5|L|||F||84100|201210111211OBX|23|NM|0147-9^ALT^BRLI^1742-6^ALANINE AMINOTRANSFERASE^LOINC||12|U/L|<41||||F||84460|201210111211OBX|24|NM|0093-5^GGTP^BRLI^2324-2^GAMMA GLUTAMYL TRANSFERASE^LOINC||8|U/L|10-71|L|||F||82977|201210111211OBX|25|NM|0058-8^Cholesterol^BRLI^2093-3^CHOLESTEROL^LOINC||149|mg/dL|<200||||F||82465|201210111211OBX|26|NM|0155-2^Triglycerides^BRLI^2571-8^TRIGLYCERIDE^LOINC||198|mg/dL|<150|H|||F||84478|201210111211OBX|27|NM|0059-6^HDL CHOL., DIRECT^BRLI^2085-9^CHOLESTEROL.IN HDL^LOINC||35||>40|L|||F||83718|201210111211OBX|28|NM|1421-7^Chol/HDL Ratio^BRLI^9830-1^CHOLESTEROL.TOTAL/CHOLESTEROL.IN HDL^LOINC||4.3||<7.4||||F||82465.01|201210111211NTE|1|L|Evaluation: AVERAGE RISKOBX|29|NM|1764-0^HDL as % of Cholesterol^BRLI^2095-8^CHOLESTEROL.IN HDL/CHOLESTEROL.TOTAL^LOINC||23|%|>14||||F||83718.01|201210111211NTE|1|L|Evaluation: AVERAGE RISKOBX|30|NM|0253-5^LDL/HDL Ratio^BRLI^11054-4^CHOLESTEROL.IN LDL/CHOLESTEROL.IN HDL^LOINC||2.11||<3.56||||F||83720.01|201210111211OBX|31|NM|0505-8^LDL Cholesterol^BRLI^2089-1^CHOLESTEROL.IN LDL^LOINC||74|mg/dL|<100||||F||83720|201210111211OBX|32|NM|3345-6^VLDL, CALCULATED^BRLI^^^LOINC||40|mg/dL|7-32|H|||F||99999|201210111211OBX|33|NM|6244-8^LDL-P TOTAL CT. (29)^BRLI^^^LOINC||1164|nmol/L|<1000|H|||F||83704|201210111211NTE|1|L|(29) NTE|2|L|LDL Particle Testing Performed at: LiposcienceNTE|3|L|                                   2500 Sumner BlvdNTE|4|L|                                   Raleigh, NC 27616OBX|34|NM|6245-5^SMALL LDL-P (29)^BRLI^43727-7^LIPOPROTEIN.BETA.SUBPARTICLE.SMALL^LOINC||542|nmol/L|<117|H|||F||83704|201210111211NTE|1|L|(29) NTE|2|L|LDL Particle Testing Performed at: LiposcienceNTE|3|L|                                   2500 Sumner BlvdNTE|4|L|                                   Raleigh, NC 27616OBX|35|NM|6243-0^LDL PARTICLE SIZE (29)^BRLI^17782-4^^LOINC||20.8|nm|>20.5||||F||83704|201210111211NTE|1|L|(29) NTE|2|L|LDL Particle Testing Performed at: LiposcienceNTE|3|L|                                   2500 Sumner BlvdNTE|4|L|                                   Raleigh, NC 27616OBX|36|NM|A125-7^HDL PARTICLE COUNT (29)^BRLI^^^LOINC||28.7|umol/L|>40.0|L|||F||99999|201210111211NTE|1|L|Small LDL-P, LDL Particle Size, and Large HDL-P have been validated byNTE|2|L|LipoScience but not cleared by US FDA; the clinical utility of theseNTE|3|L|test results has not been fully established.NTE|4|L|(29) NTE|5|L|LDL Particle Testing Performed at: LiposcienceNTE|6|L|                                   2500 Sumner BlvdNTE|7|L|                                   Raleigh, NC 27616OBX|37|ST|6288-5^HDL-P LARGE (29)^BRLI^43729-3^Lipoprotein.alpha.subparticle.large^LOINC||< 0.7|umol/L|>9.0|A|||F||99999|201210111211NTE|1|L|(29) NTE|2|L|LDL Particle Testing Performed at: LiposcienceNTE|3|L|                                   2500 Sumner BlvdNTE|4|L|                                   Raleigh, NC 27616OBX|38|NM|0457-2^APOLIPOPROTEIN B^BRLI^1884-6^APOLIPOPROTEIN B^LOINC||81|mg/dL|66-133||||F||82172|201210111211OBX|39|NM|1497-7^WBC^BRLI^6690-2^LEUKOCYTES^LOINC||7.93|x10(3)/uL|3.40-11.80||||F||85048|201210111211OBX|40|NM|1498-5^RBC^BRLI^789-8^ERYTHROCYTES^LOINC||4.46|x10(6)/uL|4.20-5.90||||F||85041|201210111211OBX|41|NM|1499-3^HGB^BRLI^718-7^HEMOGLOBIN^LOINC||13.2|gm/dL|12.3-17.0||||F||85018|201210111211OBX|42|NM|0019-0^HCT^BRLI^4544-3^HEMATOCRIT^LOINC||39.2|%|39.3-52.5|L|||F||85014|201210111211OBX|43|NM|1503-2^MCV^BRLI^787-2^MEAN CORPUSCULAR VOLUME^LOINC||87.9|fL|80.0-100.0||||F||85025.02|201210111211OBX|44|NM|1504-0^MCH^BRLI^785-6^ERYTHROCYTE MEAN CORPUSCULAR HEMOGLOBIN^LOINC||29.6|pg|25.0-34.1||||F||85025.03|201210111211OBX|45|NM|1502-4^MCHC^BRLI^786-4^ERYTHROCYTE MEAN CORPUSCULAR HEMOGLOBIN CONCENTRAT^LOINC||33.7|gm/dL|29.0-35.0||||F||85025.01|201210111211OBX|46|NM|1598-2^RDW^BRLI^788-0^ERYTHROCYTE DISTRIBUTION WIDTH^LOINC||14.9|%|10.9-16.9||||F||85029|201210111211OBX|47|NM|1505-7^POLYS^BRLI^31160-5^POLYMORPHONUCLEAR CELLS/100 LEUKOCYTES^LOINC||78.8|%|36.0-78.0|H|||F||85025.04|201210111211OBX|48|NM|1507-3^LYMPHS^BRLI^736-9^LYMPHOCYTES/100 LEUKOCYTES^LOINC||14.6|%|12.0-48.0||||F||85025.06|201210111211OBX|49|NM|1511-5^MONOS^BRLI^51384-6^Mononuclear cells/100 leukocytes^LOINC||6.1|%|0.0-13.0||||F||85025.10|201210111211OBX|50|NM|1509-9^EOS^BRLI^713-8^EOSINOPHILS/100 LEUKOCYTES^LOINC||0.1|%|0.0-8.0||||F||85025.08|201210111211OBX|51|NM|1510-7^BASOS^BRLI^706-2^BASOPHILS/100 LEUKOCYTES^LOINC||0.1|%|0.0-2.0||||F||85025.09|201210111211OBX|52|NM|270053-2^IMMATURE GRANULOCYTES^BRLI^38518-7^GRANULOCYTES.IMMATURE/100 LEUKOCYTES^LOINC||0.3|%|0.0-1.6||||F|||201210111211OBX|53|NM|0128-9^PLATELET COUNT^BRLI^777-3^PLATELETS^LOINC||317|x10(3)/uL|144-400||||F||85595|201210111211OBX|54|NM|400053-5^MPV^BRLI^32623-1^PLATELET MEAN VOLUME^LOINC||10.9|fL|8.2-11.9||||F|||201210111211OBR|22|12002556       |100478347|9893-9^ANEMIA SCREEN-EXPANDED||201210091300|201210091300|||||||201210092329||106429^RAMIREZ, CESAR|(718)334-0001|80099||BIOREFERENCE LABORATORIES||201210111211|||F||||OBX|1|NM|1497-7^WBC^BRLI^6690-2^LEUKOCYTES^LOINC||7.93|x10(3)/uL|3.40-11.80||||F||85048|201210111211OBX|2|NM|1498-5^RBC^BRLI^789-8^ERYTHROCYTES^LOINC||4.46|x10(6)/uL|4.20-5.90||||F||85041|201210111211OBX|3|NM|1499-3^HGB^BRLI^718-7^HEMOGLOBIN^LOINC||13.2|gm/dL|12.3-17.0||||F||85018|201210111211OBX|4|NM|0019-0^HCT^BRLI^4544-3^HEMATOCRIT^LOINC||39.2|%|39.3-52.5|L|||F||85014|201210111211OBX|5|NM|1503-2^MCV^BRLI^787-2^MEAN CORPUSCULAR VOLUME^LOINC||87.9|fL|80.0-100.0||||F||85025.02|201210111211OBX|6|NM|1504-0^MCH^BRLI^785-6^ERYTHROCYTE MEAN CORPUSCULAR HEMOGLOBIN^LOINC||29.6|pg|25.0-34.1||||F||85025.03|201210111211OBX|7|NM|1502-4^MCHC^BRLI^786-4^ERYTHROCYTE MEAN CORPUSCULAR HEMOGLOBIN CONCENTRAT^LOINC||33.7|gm/dL|29.0-35.0||||F||85025.01|201210111211OBX|8|NM|1598-2^RDW^BRLI^788-0^ERYTHROCYTE DISTRIBUTION WIDTH^LOINC||14.9|%|10.9-16.9||||F||85029|201210111211OBX|9|NM|1505-7^POLYS^BRLI^31160-5^POLYMORPHONUCLEAR CELLS/100 LEUKOCYTES^LOINC||78.8|%|36.0-78.0|H|||F||85025.04|201210111211OBX|10|NM|1507-3^LYMPHS^BRLI^736-9^LYMPHOCYTES/100 LEUKOCYTES^LOINC||14.6|%|12.0-48.0||||F||85025.06|201210111211OBX|11|NM|1511-5^MONOS^BRLI^51384-6^Mononuclear cells/100 leukocytes^LOINC||6.1|%|0.0-13.0||||F||85025.10|201210111211OBX|12|NM|1509-9^EOS^BRLI^713-8^EOSINOPHILS/100 LEUKOCYTES^LOINC||0.1|%|0.0-8.0||||F||85025.08|201210111211OBX|13|NM|1510-7^BASOS^BRLI^706-2^BASOPHILS/100 LEUKOCYTES^LOINC||0.1|%|0.0-2.0||||F||85025.09|201210111211OBX|14|NM|270053-2^IMMATURE GRANULOCYTES^BRLI^38518-7^GRANULOCYTES.IMMATURE/100 LEUKOCYTES^LOINC||0.3|%|0.0-1.6||||F|||201210111211OBX|15|NM|0128-9^PLATELET COUNT^BRLI^777-3^PLATELETS^LOINC||317|x10(3)/uL|144-400||||F||85595|201210111211OBX|16|NM|400053-5^MPV^BRLI^32623-1^PLATELET MEAN VOLUME^LOINC||10.9|fL|8.2-11.9||||F|||201210111211OBX|17|NM|0088-5^FERRITIN^BRLI^2276-4^FERRITIN^LOINC||43|ng/mL|22-322||||F||82728|201210111211OBX|18|NM|0090-1^FOLIC ACID^BRLI^2284-8^FOLATE^LOINC||12.08|ng/mL|>5.38||||F||82746|201210111211NTE|1|L|Folic Acid RangeNTE|2|L|                                         Units (ng/mL)NTE|3|L|             Normal                         >5.38NTE|4|L|             Borderline deficient         3.38-5.38NTE|5|L|             Deficient                    0.35-3.37NTE|6|L|             Excessive                     >24.00OBX|19|NM|0114-9^Iron^BRLI^2498-4^IRON^LOINC||57|ug/dL|45-160||||F||83540|201210111211OBX|20|NM|0141-2^RETIC COUNT^BRLI^4679-7^RETICULOCYTES/100 ERYTHROCYTES^LOINC||1.09|%|0.48-2.10||||F||85044|201210111211OBX|21|NM|0160-2^VITAMIN B12^BRLI^2132-9^COBALAMINS^LOINC||371|pg/mL|211-911||||F||82607|201210111211OBX|22|NM|0183-4^ERYTHROPOIETIN^BRLI^15061-5^ERYTHROPOIETIN^LOINC||10.0|mIU/mL|3.7-31.5||||F||82668|201210111211OBX|23|NM|0114-9^Iron^BRLI^2498-4^IRON^LOINC||57|ug/dL|45-160||||F||83540|201210111211OBX|24|NM|1114-8^Iron, % Sat.^BRLI^2502-3^IRON, % SAT. (USE PANEL 1189)^LOINC||15|%|20-55|L|||F||80002|201210111211OBX|25|NM|1889-5^TIBC^BRLI^2500-7^IRON BINDING CAPACITY^LOINC||387|ug/dL|228-428||||F||83550|201210111211OBX|26|NM|1889-5^TIBC^BRLI^2500-7^IRON BINDING CAPACITY^LOINC||387|ug/dL|228-428||||F||83550|201210111211MSH|^~&\|BioRefHMODownload-H|BIO-REFERENCE LABS|02/01/2013 -> 02/01/2013|1200239^|201302011340||ORU^R01|20130201134016.4|P|2.3|1||NE|NEPID|4|16187|106494520|RE17925K       |ABREU^JOSE||19480425|M|||3544 95TH STREET^^JACKSON HEIGHTS^NY^11372||7182056172||||||OBR|1|RE17925K       |106494520|0009-1^Lipid Screen(Basic Lipid Profile)||201201311015|201201311015|||||||201201312212||H98234^RODRIGUEZ^RAPHAEL^|(718)505-0030|80061||BIOREFERENCE LABORATORIES||201202011623|||F||||OBX|1|NM|0058-8^Cholesterol^BRLI^2093-3^CHOLESTEROL^LOINC||108|mg/dL|<200||||F||82465|201202011623OBX|2|NM|0059-6^HDL CHOL., DIRECT^BRLI^2085-9^CHOLESTEROL.IN HDL^LOINC||21||>40|L|||F||83718|201202011623OBX|3|NM|0155-2^Triglycerides^BRLI^2571-8^TRIGLYCERIDE^LOINC||74|mg/dL|<150||||F||84478|201202011623OBX|4|NM|1764-0^HDL as % of Cholesterol^BRLI^2095-8^CHOLESTEROL.IN HDL/CHOLESTEROL.TOTAL^LOINC||19|%|>14||||F|||201202011623NTE|1|L|Evaluation: AVERAGE RISKOBX|5|NM|1421-7^Chol/HDL Ratio^BRLI^9830-1^CHOLESTEROL.TOTAL/CHOLESTEROL.IN HDL^LOINC||5.1||<7.4||||F|||201202011623NTE|1|L|Evaluation: AVERAGE RISKOBX|6|NM|0253-5^LDL/HDL Ratio^BRLI^11054-4^CHOLESTEROL.IN LDL/CHOLESTEROL.IN HDL^LOINC||3.43||<3.56||||F|||201202011623OBX|7|NM|0505-8^LDL Cholesterol^BRLI^2089-1^CHOLESTEROL.IN LDL^LOINC||72|mg/dL|<100||||F||83720|201202011623OBX|8|NM|3345-6^VLDL, CALCULATED^BRLI^^^LOINC||15|mg/dL|7-32||||F||99999|201202011623OBR|2|RE17925K       |106494520|0053-9^CBC W/ Diff, Platelets||201201311015|201201311015|||||||201201312212||H98234^RODRIGUEZ^RAPHAEL^|(718)505-0030|85025||BIOREFERENCE LABORATORIES||201202011623|||F||||OBX|1|NM|1497-7^WBC^BRLI^6690-2^LEUKOCYTES^LOINC||3.38|x10(3)/uL|3.40-11.80|L|||F||85048|201202011623OBX|2|NM|1498-5^RBC^BRLI^789-8^ERYTHROCYTES^LOINC||4.14|x10(6)/uL|4.20-5.90|L|||F||85041|201202011623OBX|3|NM|1499-3^HGB^BRLI^718-7^HEMOGLOBIN^LOINC||12.7|gm/dL|12.3-17.0||||F||85018|201202011623OBX|4|NM|0019-0^HCT^BRLI^4544-3^HEMATOCRIT^LOINC||37.6|%|39.3-52.5|L|||F||85014|201202011623OBX|5|NM|1503-2^MCV^BRLI^787-2^MEAN CORPUSCULAR VOLUME^LOINC||90.8|fL|80.0-100.0||||F|||201202011623OBX|6|NM|1504-0^MCH^BRLI^785-6^ERYTHROCYTE MEAN CORPUSCULAR HEMOGLOBIN^LOINC||30.7|pg|25.0-34.1||||F|||201202011623OBX|7|NM|1502-4^MCHC^BRLI^786-4^ERYTHROCYTE MEAN CORPUSCULAR HEMOGLOBIN CONCENTRAT^LOINC||33.8|gm/dL|29.0-35.0||||F|||201202011623OBX|8|NM|1598-2^RDW^BRLI^788-0^ERYTHROCYTE DISTRIBUTION WIDTH^LOINC||13.2|%|10.9-16.9||||F||85029|201202011623OBX|9|NM|1505-7^POLYS^BRLI^31160-5^POLYMORPHONUCLEAR CELLS/100 LEUKOCYTES^LOINC||60.6|%|36.0-78.0||||F|||201202011623OBX|10|NM|1507-3^LYMPHS^BRLI^736-9^LYMPHOCYTES/100 LEUKOCYTES^LOINC||29.0|%|12.0-48.0||||F|||201202011623OBX|11|NM|1511-5^MONOS^BRLI^51384-6^Mononuclear cells/100 leukocytes^LOINC||9.2|%|0.0-13.0||||F|||201202011623OBX|12|NM|1509-9^EOS^BRLI^713-8^EOSINOPHILS/100 LEUKOCYTES^LOINC||0.3|%|0.0-8.0||||F|||201202011623OBX|13|NM|1510-7^BASOS^BRLI^706-2^BASOPHILS/100 LEUKOCYTES^LOINC||0.9|%|0.0-2.0||||F|||201202011623OBX|14|NM|270053-2^IMMATURE GRANULOCYTES^BRLI^38518-7^GRANULOCYTES.IMMATURE/100 LEUKOCYTES^LOINC||0.0|%|0.0-1.6||||F|||201202011623OBX|15|NM|0128-9^PLATELET COUNT^BRLI^777-3^PLATELETS^LOINC||134|x10(3)/uL|144-400|L|||F||85595|201202011623OBX|16|NM|400053-5^MPV^BRLI^32623-1^PLATELET MEAN VOLUME^LOINC||10.2|fL|8.2-11.9||||F|||201202011623OBR|3|RE17925K       |106494520|0102-4^Hemoglobin A1C (Glycohgb)||201201311015|201201311015|||||||201201312212||H98234^RODRIGUEZ^RAPHAEL^|(718)505-0030|83036||BIOREFERENCE LABORATORIES||201202011623|||F||||OBX|1|NM|0102-4^Hemoglobin A1C^BRLI^4548-4^HEMOGLOBIN A1C/HEMOGLOBIN.TOTAL^LOINC||8.7|%|<5.7|H|||F||83036|201202011623NTE|1|L|GLYCOHEMOGLOBIN A1C AND eAG REFERENCE RANGESNTE|2|L|                         A1C(%)     DIABETES CATEGORY*NTE|3|L|                         <5.7             Normal (non-diabetic)NTE|4|L|                        5.7-6.4           Increased risk of diabetesNTE|5|L|                         =>6.5            Consistent with diabetesNTE|6|L|                         A1C(%)     eAG(ESTIMATED AVERAGE PLASMA GLUCOSE)(mg/dL)NTE|7|L|                          6                 126NTE|8|L|                          7                 154NTE|9|L|                          8                 183NTE|10|L|                          9                 212NTE|11|L|                         10                 240NTE|12|L|                         11                 269NTE|13|L|                         12                 298NTE|14|L|                   *recommended ranges-American Diabetes Association(2010)NTE|15|L|NOTE: Previous reference range 4-6%OBR|4|RE17925K       |106494520|0142-0^RPR SEROLOGY||201201311015|201201311015|||||||201201312212||H98234^RODRIGUEZ^RAPHAEL^|(718)505-0030|86592||BIOREFERENCE LABORATORIES||201202011623|||F||||OBX|1|ST|0142-0^RPR^BRLI^11084-1^REAGIN AB^LOINC||Non-Reactive||Non-Reactive|N|||F||86592|201202011623OBR|5|RE17925K       |106494520|0153-7^Thyroid Stimulating Hormone (TSH)||201201311015|201201311015|||||||201201312212||H98234^RODRIGUEZ^RAPHAEL^|(718)505-0030|84443||BIOREFERENCE LABORATORIES||201202011623|||F||||OBX|1|NM|0153-7^TSH^BRLI^3016-3^THYROTROPIN^LOINC||8.280|uIU/mL|0.270-4.200|H|||F||84443|201202011623OBR|6|RE17925K       |106494520|0159-4^Urinalysis, Routine||201201311015|201201311015|||||||201201312212||H98234^RODRIGUEZ^RAPHAEL^|(718)505-0030|81000||BIOREFERENCE LABORATORIES||201202011623|||F||||OBX|1|ST|6315-6^Color^BRLI^5778-6^COLOR^LOINC||YELLOW||YELLOW, STRAW, AMBER|N|||F||99999|201202011623OBX|2|ST|6316-4^Character^BRLI^19244-3^CHARACTER^LOINC||CLEAR||CLEAR|N|||F||99999|201202011623OBX|3|NM|1520-6^Specific Gravity URN^BRLI^2965-2^SPECIFIC GRAVITY^LOINC||1.007||1.003 - 1.030||||F|||201202011623OBX|4|NM|1521-4^pH Urine^BRLI^2756-5^PH^LOINC||6.0||5.0 - 8.0||||F|||201202011623OBX|5|ST|1522-2^Protein, Urine^BRLI^20454-5^PROTEIN^LOINC||NEGATIVE||NEGATIVE|N|||F|||201202011623OBX|6|ST|1523-0^Glucose, Urine^BRLI^25428-4^GLUCOSE^LOINC||NEGATIVE||NEGATIVE|N|||F|||201202011623OBX|7|ST|1524-8^Ketone, Urine^BRLI^2514-8^KETONES^LOINC||NEGATIVE||NEGATIVE|N|||F|||201202011623OBX|8|NM|1525-5^Urobilinogen Urine^BRLI^19161-9^UROBILINOGEN^LOINC||0.2|Units|0.2 - 1.0||||F|||201202011623OBX|9|ST|1526-3^Bilirubin, Urine^BRLI^5770-3^BILIRUBIN^LOINC||NEGATIVE||NEGATIVE|N|||F|||201202011623OBX|10|ST|1527-1^Blood, Urine^BRLI^5794-3^HEMOGLOBIN^LOINC||NEGATIVE||NEGATIVE|N|||F|||201202011623OBX|11|ST|1528-9^Nitrites Urine^BRLI^5802-4^NITRITE^LOINC||NEGATIVE||NEGATIVE|N|||F|||201202011623OBX|12|ST|6311-5^Leukocyte Esterase^BRLI^5799-2^LEUKOCYTE ESTERASE^LOINC||NEGATIVE||NEGATIVE|N|||F||99999|201202011623OBX|13|ST|1529-7^Crystals Urine^BRLI^5782-8^CRYSTALS^LOINC||NONE||NONE|N|||F|||201202011623OBX|14|ST|2135-2^Crystal Amt. Urine^BRLI^5782-8^URINE CRYSTAL AMT.^LOINC||NONE||NONE|N|||F|||201202011623OBX|15|ST|1534-7^WBC, Urine^BRLI^5821-4^LEUKOCYTES^LOINC||0-4|PERHPF|0-4|N|||F|||201202011623OBX|16|ST|1535-4^RBC, Urine^BRLI^13945-1^ERYTHROCYTES^LOINC||NONE SEEN|PERHPF|NONE SEEN|N|||F|||201202011623OBX|17|ST|1546-1^Epithelial Cells, Ur^BRLI^20453-7^EPITHELIAL CELLS^LOINC||NONE||FEW|N|||F|||201202011623NTE|1|L|NTE|2|L|NOTE:  Significant quantities of epithelial cells willNTE|3|L|be identified if they are not squamous cell types.OBX|18|ST|1545-3^Cast, Hyaline, Urine^BRLI^5796-8^HYALINE CASTS^LOINC||NONE SEEN|PERLPF|0-4|N|||F|||201202011623OBX|19|ST|1547-9^Cast, Granular, Urin^BRLI^5793-5^GRANULAR CASTS^LOINC||NONE SEEN|PERLPF|0-1|N|||F|||201202011623OBX|20|ST|1543-8^Cast, RBC, Urine^BRLI^5807-3^ERYTHROCYTE CASTS^LOINC||NONE SEEN|PERLPF|0-1|N|||F|||201202011623OBX|21|ST|1549-5^Bacteria, Urine^BRLI^25145-4^BACTERIA^LOINC||NONE||FEW|N|||F|||201202011623OBR|7|RE17925K       |106494520|0190-9^PSA, 3rd GEN.||201201311015|201201311015|||||||201201312212||H98234^RODRIGUEZ^RAPHAEL^|(718)505-0030|84153||BIOREFERENCE LABORATORIES||201202011623|||F||||OBX|1|NM|0190-9^PSA 3rd. GEN.^BRLI^35741-8^PROSTATE SPECIFIC AG^LOINC||1.95|ng/mL|<4.00||||F||84153|201202011623NTE|1|L|NOTE: The PSA assay should not be the only test used for diagnostic purposes.NTE|2|L|      Additional evaluation using DRE, ultrasound, TUR or similar procedures mayNTE|3|L|      be used for this purpose. Predictions of disease recurrence should not beNTE|4|L|      based solely upon values obtained from serial PSA values obtained on theNTE|5|L|      patient.NTE|6|L|ASSAY INFORMATION: Method Electrochemiluminescence Immunoassay (Roche Diagnostics).OBR|8|RE17925K       |106494520|0228-7^MICROALBUMIN, URINE, RANDOM||201201311015|201201311015|||||||201201312212||H98234^RODRIGUEZ^RAPHAEL^|(718)505-0030|82042||BIOREFERENCE LABORATORIES||201202011623|||F||||OBX|1|ST|3172-4^MICROALBUMIN,RANDOM^BRLI^14957-5^ALBUMIN^LOINC||<1.2|mg/dL|Not Estab.|N|||F||82043|201202011623OBX|2|NM|1661-8^CREAT.URN.TIMED/RAND^BRLI^35674-1^Creatinine^LOINC||36.6|mg/dL|Not Estab.||||F|||201202011623OBX|3|ST|2699-7^MICROALB/CREAT RATIO^BRLI^14959-1^ALBUMIN/CREATININE^LOINC||Can't Calc|mg/gcreat|<20.0|N|||F||99999|201202011623NTE|1|L|NTE|2|L|Can't Calc: One or more components were not available or was outsideNTE|3|L|            the measurable range. We are unable to calculate.OBR|9|RE17925K       |106494520|3427-2^Comprehensive Metabolic Panel||201201311015|201201311015|||||||201201312212||H98234^RODRIGUEZ^RAPHAEL^|(718)505-0030|80099||BIOREFERENCE LABORATORIES||201202011623|||F||||OBX|1|NM|0135-4^Total Protein^BRLI^2885-2^PROTEIN^LOINC||6.7|g/dL|5.9-8.4||||F||84155|201202011623OBX|2|NM|0033-1^Albumin^BRLI^1751-7^ALBUMIN^LOINC||4.0|g/dL|3.5-5.2||||F||82040|201202011623OBX|3|NM|1753-3^Globulin^BRLI^2336-6^GLOBULIN^LOINC||2.7|g/dL|1.7-3.7||||F|||201202011623OBX|4|NM|0641-1^A/G Ratio^BRLI^1759-0^ALBUMIN/GLOBULIN^LOINC||1.5||1.1-2.9||||F|||201202011623OBX|5|NM|0148-7^Sodium^BRLI^2951-2^SODIUM^LOINC||139|mmol/L|133-145||||F||84295|201202011623OBX|6|NM|0129-7^Potassium^BRLI^2823-3^POTASSIUM^LOINC||3.5|mmol/L|3.3-5.3||||F||84132|201202011623OBX|7|NM|0057-0^Chloride^BRLI^2075-0^CHLORIDE^LOINC||102|mmol/L|96-108||||F||82435|201202011623OBX|8|NM|0052-1^CO2^BRLI^2028-9^CARBON DIOXIDE^LOINC||30|mmol/L|22-29|H|||F||82374|201202011623OBX|9|NM|0049-7^BUN^BRLI^3094-0^UREA NITROGEN^LOINC||14|mg/dL|8-23||||F||84520|201202011623OBX|10|NM|0070-3^Creatinine^BRLI^2160-0^CREATININE^LOINC||0.88|mg/dL|0.80-1.30||||F||82565|201202011623NTE|1|L|NOTE: The creatinine reference ranges have changed effective 11/7/11.OBX|11|NM|090013-4^e-GFR^BRLI^^^LOINC||87|mL/min|>60||||F|||201202011623NTE|1|L|GFR MALE/FEMALE REFERENCE RANGENTE|2|L|                                       >60 mL/min/1.73 m2NTE|3|L|NOTE: GFR (Glomerular Filtration Rate) calculation utilizes the MDRD formulaNTE|4|L|      (Modification of Diet in Renal Disease Study Group) and assumes a normalNTE|5|L|      adult body surface area of 1.73. If the patient is African AmericanNTE|6|L|      multiply result reported by 1.21. (Ref. National Kidney Disease Educa.NTE|7|L|      Program.)NTE|8|L|NOTE: A calculated GFR of <60 mL suggests chronic kidney disease, butNTE|9|L|      only if found consistently over at least 3 months. A calculatedNTE|10|L|      result of <15 mL is consistent with renal failure.OBX|12|NM|1427-4^BUN/Creat Ratio^BRLI^3097-3^UREA NITROGEN/CREATININE^LOINC||15.9||10.0-28.0||||F|||201202011623OBX|13|NM|0050-5^Calcium^BRLI^17861-6^CALCIUM^LOINC||8.9|mg/dL|8.6-10.2||||F||82310|201202011623OBX|14|NM|0043-0^Bilirubin, Total^BRLI^1975-2^BILIRUBIN^LOINC||0.4|mg/dL|0.1-1.0||||F||82247|201202011623OBX|15|NM|0185-9^Alk Phos^BRLI^6768-6^ALKALINE PHOSPHATASE^LOINC||59|U/L|40-129||||F||84075|201202011623OBX|16|NM|0146-1^AST^BRLI^1920-8^ASPARTATE AMINOTRANSFERASE^LOINC||30|U/L|<40||||F||84450|201202011623OBX|17|NM|0147-9^ALT^BRLI^1742-6^ALANINE AMINOTRANSFERASE^LOINC||23|U/L|<41||||F||84460|201202011623OBX|18|NM|1976-0^Glucose^BRLI^2345-7^GLUCOSE^LOINC||145|mg/dL|70-99|H|||F|||201202011623MSH|^~&\|BioRefHMODownload-H|BIO-REFERENCE LABS|02/01/2013 -> 02/01/2013|1200239^|201302011340||ORU^R01|20130201134016.5|P|2.3|1||NE|NEPID|5||108416402|RE17925K       |ABREU^JOSE||19480425|M|||4105 95TH ST 4B^^ELMHURST^NY^11373||7182056172||||||OBR|1|RE17925K       |108416402|0091-9^THYROXINE, FREE (FT4)||201205300000|201205300000|||||||201205302047||H46088^GARCIA^MARCO A^|(718)803-8463|84439||BIOREFERENCE LABORATORIES||201206021855|||F||||OBX|1|NM|0091-9^THYROXINE, FREE (FT4)^BRLI^3024-7^THYROXINE.FREE^LOINC||1.29|ng/dL|0.83-1.62||||F||84439|201206021855OBR|2|RE17925K       |108416402|0102-4^Hemoglobin A1C (Glycohgb)||201205300000|201205300000|||||||201205302047||H46088^GARCIA^MARCO A^|(718)803-8463|83036||BIOREFERENCE LABORATORIES||201206021855|||F||||OBX|1|NM|0102-4^Hemoglobin A1C^BRLI^4548-4^HEMOGLOBIN A1C/HEMOGLOBIN.TOTAL^LOINC||8.9|%|<5.7|H|||F||83036|201206021855NTE|1|L|GLYCOHEMOGLOBIN A1C AND eAG REFERENCE RANGESNTE|2|L|                         A1C(%)     DIABETES CATEGORY*NTE|3|L|                         <5.7             Normal (non-diabetic)NTE|4|L|                        5.7-6.4           Increased risk of diabetesNTE|5|L|                         =>6.5            Consistent with diabetesNTE|6|L|                         A1C(%)     eAG(ESTIMATED AVERAGE PLASMA GLUCOSE)(mg/dL)NTE|7|L|                          6                 126NTE|8|L|                          7                 154NTE|9|L|                          8                 183NTE|10|L|                          9                 212NTE|11|L|                         10                 240NTE|12|L|                         11                 269NTE|13|L|                         12                 298NTE|14|L|                   *recommended ranges-American Diabetes Association(2010)NTE|15|L|NOTE: Previous reference range 4-6%OBR|3|RE17925K       |108416402|0153-7^Thyroid Stimulating Hormone (TSH)||201205300000|201205300000|||||||201205302047||H46088^GARCIA^MARCO A^|(718)803-8463|84443||BIOREFERENCE LABORATORIES||201206021855|||F||||OBX|1|NM|0153-7^TSH^BRLI^3016-3^THYROTROPIN^LOINC||6.340|uIU/mL|0.270-4.200|H|||F||84443|201206021855OBR|4|RE17925K       |108416402|0190-9^PSA, 3rd GEN.||201205300000|201205300000|||||||201205302047||H46088^GARCIA^MARCO A^|(718)803-8463|84153||BIOREFERENCE LABORATORIES||201206021855|||F||||OBX|1|NM|0190-9^PSA 3rd. GEN.^BRLI^35741-8^PROSTATE SPECIFIC AG^LOINC||1.66|ng/mL|<4.00||||F||84153|201206021855NTE|1|L|NOTE: The PSA assay should not be the only test used for diagnostic purposes.NTE|2|L|      Additional evaluation using DRE, ultrasound, TUR or similar procedures mayNTE|3|L|      be used for this purpose. Predictions of disease recurrence should not beNTE|4|L|      based solely upon values obtained from serial PSA values obtained on theNTE|5|L|      patient.NTE|6|L|ASSAY INFORMATION: Method Electrochemiluminescence Immunoassay (Roche Diagnostics).OBR|5|RE17925K       |108416402|0228-7^MICROALBUMIN, URINE, RANDOM||201205300000|201205300000|||||||201205302047||H46088^GARCIA^MARCO A^|(718)803-8463|82042||BIOREFERENCE LABORATORIES||201206021855|||F||||OBX|1|ST|3172-4^MICROALBUMIN,RANDOM^BRLI^14957-5^ALBUMIN^LOINC||<1.2|mg/dL|Not Estab.|N|||F||82043|201206021855OBX|2|NM|1661-8^CREAT.URN.TIMED/RAND^BRLI^35674-1^Creatinine^LOINC||71.2|mg/dL|Not Estab.||||F|||201206021855OBX|3|ST|2699-7^MICROALB/CREAT RATIO^BRLI^14959-1^ALBUMIN/CREATININE^LOINC||Can't Calc|mg/gcreat|<30.0|N|||F||99999|201206021855NTE|1|L|NOTE: New reference range for Microalb/Creat ratio effectiveNTE|2|L|      4/16/12.NTE|3|L|NTE|4|L|Can't Calc: One or more components were not available or was outsideNTE|5|L|            the measurable range. We are unable to calculate.OBX|4|ST|0228-7^MICROALB.,URINE, RANDOM^BRLI^14957-5^ALBUMIN^LOINC||TNP|||N|||F||82042|201206021855NTE|1|L|TEST NOT PERFORMED; URINE CUP NOT RECEIVED.OBR|6|RE17925K       |108416402|0399-6^CBC W/DIFF, PLATELET CT.||201205300000|201205300000|||||||201205302047||H46088^GARCIA^MARCO A^|(718)803-8463|85025||BIOREFERENCE LABORATORIES||201206021855|||F||||OBX|1|NM|1497-7^WBC^BRLI^6690-2^LEUKOCYTES^LOINC||3.73|x10(3)/uL|3.40-11.80||||F||85048|201206021855OBX|2|NM|1498-5^RBC^BRLI^789-8^ERYTHROCYTES^LOINC||4.03|x10(6)/uL|4.20-5.90|L|||F||85041|201206021855OBX|3|NM|1499-3^HGB^BRLI^718-7^HEMOGLOBIN^LOINC||12.1|gm/dL|12.3-17.0|L|||F||85018|201206021855OBX|4|NM|0019-0^HCT^BRLI^4544-3^HEMATOCRIT^LOINC||36.5|%|39.3-52.5|L|||F||85014|201206021855OBX|5|NM|1503-2^MCV^BRLI^787-2^MEAN CORPUSCULAR VOLUME^LOINC||90.6|fL|80.0-100.0||||F|||201206021855OBX|6|NM|1504-0^MCH^BRLI^785-6^ERYTHROCYTE MEAN CORPUSCULAR HEMOGLOBIN^LOINC||30.0|pg|25.0-34.1||||F|||201206021855OBX|7|NM|1502-4^MCHC^BRLI^786-4^ERYTHROCYTE MEAN CORPUSCULAR HEMOGLOBIN CONCENTRAT^LOINC||33.2|gm/dL|29.0-35.0||||F|||201206021855OBX|8|NM|1598-2^RDW^BRLI^788-0^ERYTHROCYTE DISTRIBUTION WIDTH^LOINC||12.9|%|10.9-16.9||||F||85029|201206021855OBX|9|NM|1505-7^POLYS^BRLI^31160-5^POLYMORPHONUCLEAR CELLS/100 LEUKOCYTES^LOINC||65.6|%|36.0-78.0||||F|||201206021855OBX|10|NM|1507-3^LYMPHS^BRLI^736-9^LYMPHOCYTES/100 LEUKOCYTES^LOINC||24.4|%|12.0-48.0||||F|||201206021855OBX|11|NM|1511-5^MONOS^BRLI^51384-6^Mononuclear cells/100 leukocytes^LOINC||8.6|%|0.0-13.0||||F|||201206021855OBX|12|NM|1509-9^EOS^BRLI^713-8^EOSINOPHILS/100 LEUKOCYTES^LOINC||0.8|%|0.0-8.0||||F|||201206021855OBX|13|NM|1510-7^BASOS^BRLI^706-2^BASOPHILS/100 LEUKOCYTES^LOINC||0.3|%|0.0-2.0||||F|||201206021855OBX|14|NM|270053-2^IMMATURE GRANULOCYTES^BRLI^38518-7^GRANULOCYTES.IMMATURE/100 LEUKOCYTES^LOINC||0.3|%|0.0-1.6||||F|||201206021855OBX|15|NM|0128-9^PLATELET COUNT^BRLI^777-3^PLATELETS^LOINC||121|x10(3)/uL|144-400|L|||F||85595|201206021855OBX|16|NM|400053-5^MPV^BRLI^32623-1^PLATELET MEAN VOLUME^LOINC||11.1|fL|8.2-11.9||||F|||201206021855OBR|7|RE17925K       |108416402|0459-8^Urinalysis, Routine (w/micros)||201205300000|201205300000|||||||201205302047||H46088^GARCIA^MARCO A^|(718)803-8463|81001||BIOREFERENCE LABORATORIES||201206021855|||F||||OBX|1|ST|6315-6^Color^BRLI^5778-6^COLOR^LOINC||YELLOW||YELLOW, STRAW, AMBER|N|||F||99999|201206021855OBX|2|ST|6316-4^Character^BRLI^19244-3^CHARACTER^LOINC||CLEAR||CLEAR|N|||F||99999|201206021855OBX|3|NM|1520-6^Specific Gravity URN^BRLI^2965-2^SPECIFIC GRAVITY^LOINC||1.016||1.003 - 1.030||||F|||201206021855OBX|4|NM|1521-4^pH Urine^BRLI^2756-5^PH^LOINC||5.0||5.0 - 8.0||||F|||201206021855OBX|5|ST|1522-2^Protein, Urine^BRLI^20454-5^PROTEIN^LOINC||NEGATIVE||NEGATIVE|N|||F|||201206021855OBX|6|ST|1523-0^Glucose, Urine^BRLI^25428-4^GLUCOSE^LOINC||NEGATIVE||NEGATIVE|N|||F|||201206021855OBX|7|ST|1524-8^Ketone, Urine^BRLI^2514-8^KETONES^LOINC||NEGATIVE||NEGATIVE|N|||F|||201206021855OBX|8|NM|1525-5^Urobilinogen Urine^BRLI^19161-9^UROBILINOGEN^LOINC||0.2|Units|0.2 - 1.0||||F|||201206021855OBX|9|ST|1526-3^Bilirubin, Urine^BRLI^5770-3^BILIRUBIN^LOINC||NEGATIVE||NEGATIVE|N|||F|||201206021855OBX|10|ST|1527-1^Blood, Urine^BRLI^5794-3^HEMOGLOBIN^LOINC||NEGATIVE||NEGATIVE|N|||F|||201206021855OBX|11|ST|1528-9^Nitrites Urine^BRLI^5802-4^NITRITE^LOINC||NEGATIVE||NEGATIVE|N|||F|||201206021855OBX|12|ST|6311-5^Leukocyte Esterase^BRLI^5799-2^LEUKOCYTE ESTERASE^LOINC||NEGATIVE||NEGATIVE|N|||F||99999|201206021855OBX|13|ST|1529-7^Crystals Urine^BRLI^5782-8^CRYSTALS^LOINC||NONE||NONE|N|||F|||201206021855OBX|14|ST|2135-2^Crystal Amt. Urine^BRLI^5782-8^URINE CRYSTAL AMT.^LOINC||NONE||NONE|N|||F|||201206021855OBX|15|ST|1534-7^WBC, Urine^BRLI^5821-4^LEUKOCYTES^LOINC||0-4|PERHPF|0-4|N|||F|||201206021855OBX|16|ST|1535-4^RBC, Urine^BRLI^13945-1^ERYTHROCYTES^LOINC||NONE SEEN|PERHPF|NONE SEEN|N|||F|||201206021855OBX|17|ST|1546-1^Epithelial Cells, Ur^BRLI^20453-7^EPITHELIAL CELLS^LOINC||NONE||FEW|N|||F|||201206021855NTE|1|L|NTE|2|L|NOTE:  Significant quantities of epithelial cells willNTE|3|L|be identified if they are not squamous cell types.OBX|18|ST|1545-3^Cast, Hyaline, Urine^BRLI^5796-8^HYALINE CASTS^LOINC||0-4|PERLPF|0-4|N|||F|||201206021855OBX|19|ST|1547-9^Cast, Granular, Urin^BRLI^5793-5^GRANULAR CASTS^LOINC||NONE SEEN|PERLPF|0-1|N|||F|||201206021855OBX|20|ST|1543-8^Cast, RBC, Urine^BRLI^5807-3^ERYTHROCYTE CASTS^LOINC||NONE SEEN|PERLPF|0-1|N|||F|||201206021855OBX|21|ST|1549-5^Bacteria, Urine^BRLI^25145-4^BACTERIA^LOINC||NONE||FEW|N|||F|||201206021855OBX|22|ST|0459-8^URINALYSIS, COMPLETE^BRLI^^^LOINC||TNP|||N|||F||81001|201206021855NTE|1|L|TEST NOT PERFORMED; URINE URINALYSIS TUBE - YELLOW NOT RECEIVED.OBR|8|RE17925K       |108416402|9753-5^ACT 4 (ACT 2 and ChemProfile 24 and CBC)||201205300000|201205300000|||||||201205302047||H46088^GARCIA^MARCO A^|(718)803-8463|80099||BIOREFERENCE LABORATORIES||201206021855|||F||||OBX|1|NM|0135-4^Total Protein^BRLI^2885-2^PROTEIN^LOINC||6.9|g/dL|5.9-8.4||||F||84155|201206021855OBX|2|NM|0033-1^Albumin^BRLI^1751-7^ALBUMIN^LOINC||4.1|g/dL|3.5-5.2||||F||82040|201206021855OBX|3|NM|1753-3^Globulin^BRLI^2336-6^GLOBULIN^LOINC||2.8|g/dL|1.7-3.7||||F|||201206021855OBX|4|NM|0641-1^A/G Ratio^BRLI^1759-0^ALBUMIN/GLOBULIN^LOINC||1.5||1.1-2.9||||F|||201206021855OBX|5|NM|1976-0^Glucose^BRLI^2345-7^GLUCOSE^LOINC||170|mg/dL|70-99|H|||F|||201206021855OBX|6|NM|0148-7^Sodium^BRLI^2951-2^SODIUM^LOINC||139|mmol/L|133-145||||F||84295|201206021855OBX|7|NM|0129-7^Potassium^BRLI^2823-3^POTASSIUM^LOINC||3.9|mmol/L|3.3-5.3||||F||84132|201206021855OBX|8|NM|0057-0^Chloride^BRLI^2075-0^CHLORIDE^LOINC||101|mmol/L|96-108||||F||82435|201206021855OBX|9|NM|0052-1^CO2^BRLI^2028-9^CARBON DIOXIDE^LOINC||26|mmol/L|22-29||||F||82374|201206021855OBX|10|NM|0049-7^BUN^BRLI^3094-0^UREA NITROGEN^LOINC||19|mg/dL|8-23||||F||84520|201206021855OBX|11|NM|0070-3^Creatinine^BRLI^2160-0^CREATININE^LOINC||0.93|mg/dL|0.80-1.30||||F||82565|201206021855NTE|1|L|NOTE: The creatinine reference ranges have changed effective 11/7/11.OBX|12|NM|090013-4^e-GFR^BRLI^^^LOINC||82|mL/min|>60||||F|||201206021855OBX|13|NM|090015-9^e-GFR, African American^BRLI^^^LOINC||99|mL/min|>60||||F|||201206021855OBX|14|NM|1427-4^BUN/Creat Ratio^BRLI^3097-3^UREA NITROGEN/CREATININE^LOINC||20.4||10.0-28.0||||F|||201206021855OBX|15|NM|0050-5^Calcium^BRLI^17861-6^CALCIUM^LOINC||9.1|mg/dL|8.6-10.2||||F||82310|201206021855OBX|16|NM|0157-8^Uric Acid^BRLI^3084-1^URATE^LOINC||4.3|mg/dL|3.4-7.0||||F||84550|201206021855OBX|17|NM|0114-9^Iron^BRLI^2498-4^IRON^LOINC||63|ug/dL|45-160||||F||83540|201206021855OBX|18|NM|0043-0^Bilirubin, Total^BRLI^1975-2^BILIRUBIN^LOINC||0.3|mg/dL|0.1-1.0||||F||82247|201206021855OBX|19|NM|0117-2^LD^BRLI^2532-0^LACTATE DEHYDROGENASE^LOINC||163|U/L|135-225||||F||83615|201206021855OBX|20|NM|0185-9^Alk Phos^BRLI^6768-6^ALKALINE PHOSPHATASE^LOINC||69|U/L|40-129||||F||84075|201206021855OBX|21|NM|0146-1^AST^BRLI^1920-8^ASPARTATE AMINOTRANSFERASE^LOINC||25|U/L|<40||||F||84450|201206021855OBX|22|NM|0127-1^Phosphorus^BRLI^2777-1^PHOSPHATE^LOINC||3.7|mg/dL|2.7-4.5||||F||84100|201206021855OBX|23|NM|0147-9^ALT^BRLI^1742-6^ALANINE AMINOTRANSFERASE^LOINC||24|U/L|<41||||F||84460|201206021855OBX|24|NM|0093-5^GGTP^BRLI^2324-2^GAMMA GLUTAMYL TRANSFERASE^LOINC||9|U/L|10-71|L|||F||82977|201206021855OBX|25|NM|0058-8^Cholesterol^BRLI^2093-3^CHOLESTEROL^LOINC||82|mg/dL|<200||||F||82465|201206021855OBX|26|NM|0155-2^Triglycerides^BRLI^2571-8^TRIGLYCERIDE^LOINC||64|mg/dL|<150||||F||84478|201206021855OBX|27|NM|0059-6^HDL CHOL., DIRECT^BRLI^2085-9^CHOLESTEROL.IN HDL^LOINC||24||>40|L|||F||83718|201206021855OBX|28|NM|1764-0^HDL as % of Cholesterol^BRLI^2095-8^CHOLESTEROL.IN HDL/CHOLESTEROL.TOTAL^LOINC||29|%|>14||||F|||201206021855NTE|1|L|Evaluation: BELOW AVERAGE RISKOBX|29|NM|1421-7^Chol/HDL Ratio^BRLI^9830-1^CHOLESTEROL.TOTAL/CHOLESTEROL.IN HDL^LOINC||3.4||<7.4||||F|||201206021855NTE|1|L|Evaluation: BELOW AVERAGE RISKOBX|30|NM|0253-5^LDL/HDL Ratio^BRLI^11054-4^CHOLESTEROL.IN LDL/CHOLESTEROL.IN HDL^LOINC||2.00||<3.56||||F|||201206021855OBX|31|NM|3345-6^VLDL, CALCULATED^BRLI^^^LOINC||13|mg/dL|7-32||||F||99999|201206021855OBX|32|NM|2194-9^LIPOPROT. (LDL) DIRECT^BRLI^18262-6^CHOLESTEROL.IN LDL^LOINC||48|mg/dL|<100||||F|||201206021855OBX|33|NM|6244-8^LDL-P TOTAL CT. (29)^BRLI^^^LOINC||730|nmol/L|<1000||||F||83704|201206021855NTE|1|L|(29) NTE|2|L|LDL Particle Testing Performed at: LiposcienceNTE|3|L|                                   2500 Sumner BlvdNTE|4|L|                                   Raleigh, NC 27616OBX|34|NM|6245-5^SMALL LDL-P (29)^BRLI^43727-7^LIPOPROTEIN.BETA.SUBPARTICLE.SMALL^LOINC||468|nmol/L|<117|H|||F||83704|201206021855NTE|1|L|(29) NTE|2|L|LDL Particle Testing Performed at: LiposcienceNTE|3|L|                                   2500 Sumner BlvdNTE|4|L|                                   Raleigh, NC 27616OBX|35|NM|6243-0^LDL PARTICLE SIZE (29)^BRLI^17782-4^^LOINC||20.2|nm|>20.5|L|||F||83704|201206021855NTE|1|L|(29) NTE|2|L|LDL Particle Testing Performed at: LiposcienceNTE|3|L|                                   2500 Sumner BlvdNTE|4|L|                                   Raleigh, NC 27616OBX|36|NM|A125-7^HDL PARTICLE COUNT (29)^BRLI^^^LOINC||17.1|umol/L|>40.0|L|||F||99999|201206021855NTE|1|L|Small LDL-P, LDL Particle Size, and Large HDL-P have been validated byNTE|2|L|LipoScience but not cleared by US FDA; the clinical utility of theseNTE|3|L|test results has not been fully established.NTE|4|L|(29) NTE|5|L|LDL Particle Testing Performed at: LiposcienceNTE|6|L|                                   2500 Sumner BlvdNTE|7|L|                                   Raleigh, NC 27616OBX|37|NM|6288-5^HDL-P LARGE (29)^BRLI^43729-3^Lipoprotein.alpha.subparticle.large^LOINC||3.0|umol/L|>9.0|L|||F||99999|201206021855NTE|1|L|(29) NTE|2|L|LDL Particle Testing Performed at: LiposcienceNTE|3|L|                                   2500 Sumner BlvdNTE|4|L|                                   Raleigh, NC 27616OBX|38|NM|0451-5^APOLIPOPROTEIN A1^BRLI^1869-7^APOLIPOPROTEIN A-I^LOINC||73|mg/dL|104-202|L|||F||82172|201206021855OBX|39|NM|0457-2^APOLIPOPROTEIN B^BRLI^1884-6^APOLIPOPROTEIN B^LOINC||47|mg/dL|66-133|L|||F||82172|201206021855OBX|40|NM|0458-0^APO. B/A1 Ratio^BRLI^13462-7^APOLIPOPROTEIN A-I/APOLIPOPROTEIN B^LOINC||0.64||0.45-1.25||||F||82172|201206021855OBX|41|NM|1639-4^LIPOPROTEIN-a^BRLI^10835-7^LIPOPROTEIN (LITTLE A)^LOINC||34.3|mg/dL|<30.0|H|||F||82172|201206021855OBX|42|ST|3320-9^hsCRP^BRLI^30522-7^C REACTIVE PROTEIN^LOINC||<0.2|mg/L|See Below|N|||F||86140|201206021855NTE|1|L|HIGH SENSITIVITY CRP (hsCRP) (test#3320) REFERENCE RANGESNTE|2|L|                      Range (mg/L)     Relative Risk of Future MI or StrokeNTE|3|L|                         <1.0                  LOWNTE|4|L|                        1.0-3.0                AVERAGENTE|5|L|                          >3.0                 HIGHOBX|43|NM|6155-6^Lp-PLA2^BRLI^39804-0^LIPOPROTEIN ASSOCIATED PHOSPHOLIPASE A2^LOINC||66|ng/mL|<200||||F||83520|201206021855OBX|44|NM|1497-7^WBC^BRLI^6690-2^LEUKOCYTES^LOINC||3.73|x10(3)/uL|3.40-11.80||||F||85048|201206021855OBX|45|NM|1498-5^RBC^BRLI^789-8^ERYTHROCYTES^LOINC||4.03|x10(6)/uL|4.20-5.90|L|||F||85041|201206021855OBX|46|NM|1499-3^HGB^BRLI^718-7^HEMOGLOBIN^LOINC||12.1|gm/dL|12.3-17.0|L|||F||85018|201206021855OBX|47|NM|0019-0^HCT^BRLI^4544-3^HEMATOCRIT^LOINC||36.5|%|39.3-52.5|L|||F||85014|201206021855OBX|48|NM|1503-2^MCV^BRLI^787-2^MEAN CORPUSCULAR VOLUME^LOINC||90.6|fL|80.0-100.0||||F|||201206021855OBX|49|NM|1504-0^MCH^BRLI^785-6^ERYTHROCYTE MEAN CORPUSCULAR HEMOGLOBIN^LOINC||30.0|pg|25.0-34.1||||F|||201206021855OBX|50|NM|1502-4^MCHC^BRLI^786-4^ERYTHROCYTE MEAN CORPUSCULAR HEMOGLOBIN CONCENTRAT^LOINC||33.2|gm/dL|29.0-35.0||||F|||201206021855OBX|51|NM|1598-2^RDW^BRLI^788-0^ERYTHROCYTE DISTRIBUTION WIDTH^LOINC||12.9|%|10.9-16.9||||F||85029|201206021855OBX|52|NM|1505-7^POLYS^BRLI^31160-5^POLYMORPHONUCLEAR CELLS/100 LEUKOCYTES^LOINC||65.6|%|36.0-78.0||||F|||201206021855OBX|53|NM|1507-3^LYMPHS^BRLI^736-9^LYMPHOCYTES/100 LEUKOCYTES^LOINC||24.4|%|12.0-48.0||||F|||201206021855OBX|54|NM|1511-5^MONOS^BRLI^51384-6^Mononuclear cells/100 leukocytes^LOINC||8.6|%|0.0-13.0||||F|||201206021855OBX|55|NM|1509-9^EOS^BRLI^713-8^EOSINOPHILS/100 LEUKOCYTES^LOINC||0.8|%|0.0-8.0||||F|||201206021855OBX|56|NM|1510-7^BASOS^BRLI^706-2^BASOPHILS/100 LEUKOCYTES^LOINC||0.3|%|0.0-2.0||||F|||201206021855OBX|57|NM|270053-2^IMMATURE GRANULOCYTES^BRLI^38518-7^GRANULOCYTES.IMMATURE/100 LEUKOCYTES^LOINC||0.3|%|0.0-1.6||||F|||201206021855OBX|58|NM|0128-9^PLATELET COUNT^BRLI^777-3^PLATELETS^LOINC||121|x10(3)/uL|144-400|L|||F||85595|201206021855OBX|59|NM|400053-5^MPV^BRLI^32623-1^PLATELET MEAN VOLUME^LOINC||11.1|fL|8.2-11.9||||F|||201206021855MSH|^~&\|BioRefHMODownload-H|BIO-REFERENCE LABS|02/01/2013 -> 02/01/2013|1200239^|201302011340||ORU^R01|20130201134016.6|P|2.3|1||NE|NEPID|6||109700304|RE17925K       |ABREU^JOSE||19480425|M|||4105 95 ST 4B^^ELMHURST^NY^11373||7182056172||||||NTE|1|P|PATIENT FASTINGOBR|1|RE17925K       |109700304|0005-9^CHEM 24 (SMAC)||201208210000|201208210000|||||||201208212233||H46088^GARCIA^MARCO A^|(718)803-8463|G0059||BIOREFERENCE LABORATORIES||201208221418|||F||||OBX|1|NM|0135-4^Total Protein^BRLI^2885-2^PROTEIN^LOINC||7.1|g/dL|5.9-8.4||||F||84155|201208221418OBX|2|NM|0033-1^Albumin^BRLI^1751-7^ALBUMIN^LOINC||4.3|g/dL|3.5-5.2||||F||82040|201208221418OBX|3|NM|1753-3^Globulin^BRLI^2336-6^GLOBULIN^LOINC||2.8|g/dL|1.7-3.7||||F||G0059.02|201208221418OBX|4|NM|0641-1^A/G Ratio^BRLI^1759-0^ALBUMIN/GLOBULIN^LOINC||1.5||1.1-2.9||||F||G0059.04|201208221418OBX|5|NM|1976-0^Glucose^BRLI^2345-7^GLUCOSE^LOINC||209|mg/dL|70-99|H|||F||82947.01|201208221418OBX|6|NM|0148-7^Sodium^BRLI^2951-2^SODIUM^LOINC||134|mmol/L|133-145||||F||84295|201208221418OBX|7|NM|0129-7^Potassium^BRLI^2823-3^POTASSIUM^LOINC||4.2|mmol/L|3.3-5.3||||F||84132|201208221418OBX|8|NM|0057-0^Chloride^BRLI^2075-0^CHLORIDE^LOINC||98|mmol/L|96-108||||F||82435|201208221418OBX|9|NM|0052-1^CO2^BRLI^2028-9^CARBON DIOXIDE^LOINC||28|mmol/L|22-29||||F||82374|201208221418OBX|10|NM|0049-7^BUN^BRLI^3094-0^UREA NITROGEN^LOINC||22|mg/dL|8-23||||F||84520|201208221418OBX|11|NM|0070-3^Creatinine^BRLI^2160-0^CREATININE^LOINC||0.95|mg/dL|0.80-1.30||||F||82565|201208221418OBX|12|NM|090013-4^e-GFR^BRLI^^^LOINC||80|mL/min|>60||||F|||201208221418OBX|13|NM|090015-9^e-GFR, African American^BRLI^^^LOINC||97|mL/min|>60||||F|||201208221418OBX|14|NM|1427-4^BUN/Creat Ratio^BRLI^3097-3^UREA NITROGEN/CREATININE^LOINC||23.2||10.0-28.0||||F||G0059.01|201208221418OBX|15|NM|0050-5^Calcium^BRLI^17861-6^CALCIUM^LOINC||9.2|mg/dL|8.6-10.2||||F||82310|201208221418OBX|16|NM|0157-8^Uric Acid^BRLI^3084-1^URATE^LOINC||4.7|mg/dL|3.4-7.0||||F||84550|201208221418OBX|17|NM|0114-9^Iron^BRLI^2498-4^IRON^LOINC||69|ug/dL|45-160||||F||83540|201208221418OBX|18|NM|0043-0^Bilirubin, Total^BRLI^1975-2^BILIRUBIN^LOINC||0.4|mg/dL|0.1-1.0||||F||82247|201208221418OBX|19|NM|0117-2^LD^BRLI^2532-0^LACTATE DEHYDROGENASE^LOINC||152|U/L|135-225||||F||83615|201208221418OBX|20|NM|0185-9^Alk Phos^BRLI^6768-6^ALKALINE PHOSPHATASE^LOINC||67|U/L|40-129||||F||84075|201208221418OBX|21|NM|0146-1^AST^BRLI^1920-8^ASPARTATE AMINOTRANSFERASE^LOINC||17|U/L|<40||||F||84450|201208221418OBX|22|NM|0127-1^Phosphorus^BRLI^2777-1^PHOSPHATE^LOINC||3.9|mg/dL|2.7-4.5||||F||84100|201208221418OBX|23|NM|0147-9^ALT^BRLI^1742-6^ALANINE AMINOTRANSFERASE^LOINC||19|U/L|<41||||F||84460|201208221418OBX|24|NM|0093-5^GGTP^BRLI^2324-2^GAMMA GLUTAMYL TRANSFERASE^LOINC||9|U/L|10-71|L|||F||82977|201208221418OBX|25|NM|0058-8^Cholesterol^BRLI^2093-3^CHOLESTEROL^LOINC||147|mg/dL|<200||||F||82465|201208221418OBX|26|NM|0155-2^Triglycerides^BRLI^2571-8^TRIGLYCERIDE^LOINC||166|mg/dL|<150|H|||F||84478|201208221418OBR|2|RE17925K       |109700304|0009-1^Lipid Screen(Basic Lipid Profile)||201208210000|201208210000|||||||201208212233||H46088^GARCIA^MARCO A^|(718)803-8463|80061||BIOREFERENCE LABORATORIES||201208221418|||F||||OBX|1|NM|0058-8^Cholesterol^BRLI^2093-3^CHOLESTEROL^LOINC||147|mg/dL|<200||||F||82465|201208221418OBX|2|NM|0059-6^HDL CHOL., DIRECT^BRLI^2085-9^CHOLESTEROL.IN HDL^LOINC||23||>40|L|||F||83718|201208221418OBX|3|NM|0155-2^Triglycerides^BRLI^2571-8^TRIGLYCERIDE^LOINC||166|mg/dL|<150|H|||F||84478|201208221418OBX|4|NM|1764-0^HDL as % of Cholesterol^BRLI^2095-8^CHOLESTEROL.IN HDL/CHOLESTEROL.TOTAL^LOINC||16|%|>14||||F||83718.01|201208221418NTE|1|L|Evaluation: AVERAGE RISKOBX|5|NM|1421-7^Chol/HDL Ratio^BRLI^9830-1^CHOLESTEROL.TOTAL/CHOLESTEROL.IN HDL^LOINC||6.4||<7.4||||F||82465.01|201208221418NTE|1|L|Evaluation: AVERAGE RISKOBX|6|NM|0253-5^LDL/HDL Ratio^BRLI^11054-4^CHOLESTEROL.IN LDL/CHOLESTEROL.IN HDL^LOINC||4.39||<3.56|H|||F||83720.01|201208221418OBX|7|NM|0505-8^LDL Cholesterol^BRLI^2089-1^CHOLESTEROL.IN LDL^LOINC||91|mg/dL|<100||||F||83720|201208221418OBX|8|NM|3345-6^VLDL, CALCULATED^BRLI^^^LOINC||33|mg/dL|7-32|H|||F||99999|201208221418OBR|3|RE17925K       |109700304|0091-9^THYROXINE, FREE (FT4)||201208210000|201208210000|||||||201208212233||H46088^GARCIA^MARCO A^|(718)803-8463|84439||BIOREFERENCE LABORATORIES||201208221418|||F||||OBX|1|NM|0091-9^THYROXINE, FREE (FT4)^BRLI^3024-7^THYROXINE.FREE^LOINC||1.14|ng/dL|0.83-1.62||||F||84439|201208221418OBR|4|RE17925K       |109700304|0102-4^Hemoglobin A1C (Glycohgb)||201208210000|201208210000|||||||201208212233||H46088^GARCIA^MARCO A^|(718)803-8463|83036||BIOREFERENCE LABORATORIES||201208221418|||F||||OBX|1|NM|0102-4^Hemoglobin A1C^BRLI^4548-4^HEMOGLOBIN A1C/HEMOGLOBIN.TOTAL^LOINC||9.1|%|<5.7|H|||F||83036|201208221418NTE|1|L|GLYCOHEMOGLOBIN A1C AND eAG REFERENCE RANGESNTE|2|L|                         A1C(%)     DIABETES CATEGORY*NTE|3|L|                         <5.7             Normal (non-diabetic)NTE|4|L|                        5.7-6.4           Increased risk of diabetesNTE|5|L|                         =>6.5            Consistent with diabetesNTE|6|L|                         A1C(%)     eAG(ESTIMATED AVERAGE PLASMA GLUCOSE)(mg/dL)NTE|7|L|                          6                 126NTE|8|L|                          7                 154NTE|9|L|                          8                 183NTE|10|L|                          9                 212NTE|11|L|                         10                 240NTE|12|L|                         11                 269NTE|13|L|                         12                 298NTE|14|L|                   *recommended ranges-American Diabetes Association(2010)NTE|15|L|NOTE: Previous reference range 4-6%OBR|5|RE17925K       |109700304|0153-7^Thyroid Stimulating Hormone (TSH)||201208210000|201208210000|||||||201208212233||H46088^GARCIA^MARCO A^|(718)803-8463|84443||BIOREFERENCE LABORATORIES||201208221418|||F||||OBX|1|NM|0153-7^TSH^BRLI^3016-3^THYROTROPIN^LOINC||5.990|uIU/mL|0.270-4.200|H|||F||84443|201208221418OBR|6|RE17925K       |109700304|0190-9^PSA, 3rd GEN.||201208210000|201208210000|||||||201208212233||H46088^GARCIA^MARCO A^|(718)803-8463|84153||BIOREFERENCE LABORATORIES||201208221418|||F||||OBX|1|NM|0190-9^PSA 3rd. GEN.^BRLI^35741-8^PROSTATE SPECIFIC AG^LOINC||2.05|ng/mL|<4.00||||F||84153|201208221418NTE|1|L|NOTE: The PSA assay should not be the only test used for diagnostic purposes.NTE|2|L|      Additional evaluation using DRE, ultrasound, TUR or similar procedures mayNTE|3|L|      be used for this purpose. Predictions of disease recurrence should not beNTE|4|L|      based solely upon values obtained from serial PSA values obtained on theNTE|5|L|      patient.NTE|6|L|ASSAY INFORMATION: Method Electrochemiluminescence Immunoassay (Roche Diagnostics).OBR|7|RE17925K       |109700304|0228-7^MICROALBUMIN, URINE, RANDOM||201208210000|201208210000|||||||201208212233||H46088^GARCIA^MARCO A^|(718)803-8463|82042||BIOREFERENCE LABORATORIES||201208221418|||F||||OBX|1|NM|3172-4^MICROALBUMIN,RANDOM^BRLI^14957-5^ALBUMIN^LOINC||1.2|mg/dL|Not Estab.||||F||82043|201208221418OBX|2|NM|1661-8^CREAT.URN.TIMED/RAND^BRLI^35674-1^Creatinine^LOINC||77.8|mg/dL|Not Estab.||||F||82570,80002|201208221418OBX|3|NM|2699-7^MICROALB/CREAT RATIO^BRLI^14959-1^ALBUMIN/CREATININE^LOINC||15.4|mg/gcreat|<30.0||||F||99999|201208221418NTE|1|L|NOTE: New reference range for Microalb/Creat ratio effectiveNTE|2|L|      4/16/12.OBR|8|RE17925K       |109700304|0286-5^Vitamin D, 25-Hydroxy, Serum||201208210000|201208210000|||||||201208212233||H46088^GARCIA^MARCO A^|(718)803-8463|82307||BIOREFERENCE LABORATORIES||201208221418|||F||||OBX|1|NM|0286-5^25OH, VITAMIN D^BRLI^62292-8^CALCIDIOL^LOINC||12.0|ng/mL|32.0-100.0|L|||F||82307|201208221418OBR|9|RE17925K       |109700304|0399-6^CBC W/DIFF, PLATELET CT.||201208210000|201208210000|||||||201208212233||H46088^GARCIA^MARCO A^|(718)803-8463|85025||BIOREFERENCE LABORATORIES||201208221418|||F||||OBX|1|NM|1497-7^WBC^BRLI^6690-2^LEUKOCYTES^LOINC||3.83|x10(3)/uL|3.40-11.80||||F||85048|201208221418OBX|2|NM|1498-5^RBC^BRLI^789-8^ERYTHROCYTES^LOINC||4.24|x10(6)/uL|4.20-5.90||||F||85041|201208221418OBX|3|NM|1499-3^HGB^BRLI^718-7^HEMOGLOBIN^LOINC||13.1|gm/dL|12.3-17.0||||F||85018|201208221418OBX|4|NM|0019-0^HCT^BRLI^4544-3^HEMATOCRIT^LOINC||38.8|%|39.3-52.5|L|||F||85014|201208221418OBX|5|NM|1503-2^MCV^BRLI^787-2^MEAN CORPUSCULAR VOLUME^LOINC||91.5|fL|80.0-100.0||||F||85025.02|201208221418OBX|6|NM|1504-0^MCH^BRLI^785-6^ERYTHROCYTE MEAN CORPUSCULAR HEMOGLOBIN^LOINC||30.9|pg|25.0-34.1||||F||85025.03|201208221418OBX|7|NM|1502-4^MCHC^BRLI^786-4^ERYTHROCYTE MEAN CORPUSCULAR HEMOGLOBIN CONCENTRAT^LOINC||33.8|gm/dL|29.0-35.0||||F||85025.01|201208221418OBX|8|NM|1598-2^RDW^BRLI^788-0^ERYTHROCYTE DISTRIBUTION WIDTH^LOINC||13.8|%|10.9-16.9||||F||85029|201208221418OBX|9|NM|1505-7^POLYS^BRLI^31160-5^POLYMORPHONUCLEAR CELLS/100 LEUKOCYTES^LOINC||63.3|%|36.0-78.0||||F||85025.04|201208221418OBX|10|NM|1507-3^LYMPHS^BRLI^736-9^LYMPHOCYTES/100 LEUKOCYTES^LOINC||26.4|%|12.0-48.0||||F||85025.06|201208221418OBX|11|NM|1511-5^MONOS^BRLI^51384-6^Mononuclear cells/100 leukocytes^LOINC||8.1|%|0.0-13.0||||F||85025.10|201208221418OBX|12|NM|1509-9^EOS^BRLI^713-8^EOSINOPHILS/100 LEUKOCYTES^LOINC||1.6|%|0.0-8.0||||F||85025.08|201208221418OBX|13|NM|1510-7^BASOS^BRLI^706-2^BASOPHILS/100 LEUKOCYTES^LOINC||0.3|%|0.0-2.0||||F||85025.09|201208221418OBX|14|NM|270053-2^IMMATURE GRANULOCYTES^BRLI^38518-7^GRANULOCYTES.IMMATURE/100 LEUKOCYTES^LOINC||0.3|%|0.0-1.6||||F|||201208221418OBX|15|NM|0128-9^PLATELET COUNT^BRLI^777-3^PLATELETS^LOINC||130|x10(3)/uL|144-400|L|||F||85595|201208221418OBX|16|NM|400053-5^MPV^BRLI^32623-1^PLATELET MEAN VOLUME^LOINC||10.4|fL|8.2-11.9||||F|||201208221418OBR|10|RE17925K       |109700304|0459-8^Urinalysis, Routine (w/micros)||201208210000|201208210000|||||||201208212233||H46088^GARCIA^MARCO A^|(718)803-8463|81001||BIOREFERENCE LABORATORIES||201208221418|||F||||OBX|1|ST|6315-6^Color^BRLI^5778-6^COLOR^LOINC||YELLOW||YELLOW, STRAW, AMBER|N|||F||99999|201208221418OBX|2|ST|6316-4^Character^BRLI^19244-3^CHARACTER^LOINC||CLEAR||CLEAR|N|||F||99999|201208221418OBX|3|NM|1520-6^Specific Gravity URN^BRLI^2965-2^SPECIFIC GRAVITY^LOINC||1.016||1.003 - 1.030||||F||81001.03|201208221418OBX|4|NM|1521-4^pH Urine^BRLI^2756-5^PH^LOINC||5.0||5.0 - 8.0||||F||81001.04|201208221418OBX|5|ST|1522-2^Protein, Urine^BRLI^20454-5^PROTEIN^LOINC||NEGATIVE||NEGATIVE|N|||F||81001.05|201208221418OBX|6|ST|1523-0^Glucose, Urine^BRLI^25428-4^GLUCOSE^LOINC||TRACE,100 mg/dL||NEGATIVE|A|||F||81001.06|201208221418OBX|7|ST|1524-8^Ketone, Urine^BRLI^2514-8^KETONES^LOINC||NEGATIVE||NEGATIVE|N|||F||81001.07|201208221418OBX|8|NM|1525-5^Urobilinogen Urine^BRLI^19161-9^UROBILINOGEN^LOINC||0.2|Units|0.2 - 1.0||||F||81001.08|201208221418OBX|9|ST|1526-3^Bilirubin, Urine^BRLI^5770-3^BILIRUBIN^LOINC||NEGATIVE||NEGATIVE|N|||F||81001.09|201208221418OBX|10|ST|1527-1^Blood, Urine^BRLI^5794-3^HEMOGLOBIN^LOINC||NEGATIVE||NEGATIVE|N|||F||81001.1|201208221418OBX|11|ST|1528-9^Nitrites Urine^BRLI^5802-4^NITRITE^LOINC||NEGATIVE||NEGATIVE|N|||F||81001.11|201208221418OBX|12|ST|6311-5^Leukocyte Esterase^BRLI^5799-2^LEUKOCYTE ESTERASE^LOINC||NEGATIVE||NEGATIVE|N|||F||99999|201208221418OBX|13|ST|1529-7^Crystals Urine^BRLI^5782-8^CRYSTALS^LOINC||NONE||NONE|N|||F||81001.12|201208221418OBX|14|ST|2135-2^Crystal Amt. Urine^BRLI^5782-8^URINE CRYSTAL AMT.^LOINC||NONE||NONE|N|||F||81000.34|201208221418OBX|15|ST|1534-7^WBC, Urine^BRLI^5821-4^LEUKOCYTES^LOINC||0-4|PERHPF|0-4|N|||F||81001.17|201208221418OBX|16|ST|1535-4^RBC, Urine^BRLI^13945-1^ERYTHROCYTES^LOINC||NONE SEEN|PERHPF|NONE SEEN|N|||F||81001.18|201208221418OBX|17|ST|1546-1^Epithelial Cells, Ur^BRLI^20453-7^EPITHELIAL CELLS^LOINC||NONE||FEW|N|||F||81001.28|201208221418NTE|1|L|NTE|2|L|NOTE:  Significant quantities of epithelial cells willNTE|3|L|be identified if they are not squamous cell types.OBX|18|ST|1545-3^Cast, Hyaline, Urine^BRLI^5796-8^HYALINE CASTS^LOINC||0-4|PERLPF|0-4|N|||F||81001.27|201208221418OBX|19|ST|1547-9^Cast, Granular, Urin^BRLI^5793-5^GRANULAR CASTS^LOINC||NONE SEEN|PERLPF|0-1|N|||F||81001.29|201208221418OBX|20|ST|1543-8^Cast, RBC, Urine^BRLI^5807-3^ERYTHROCYTE CASTS^LOINC||NONE SEEN|PERLPF|0-1|N|||F||81001.25|201208221418OBX|21|ST|1549-5^Bacteria, Urine^BRLI^25145-4^BACTERIA^LOINC||FEW||FEW|N|||F||81001.31|201208221418OBR|11|RE17925K       |109700304|2194-9^LDL Direct||201208210000|201208210000|||||||201208212233||H46088^GARCIA^MARCO A^|(718)803-8463|82565,84478,83716||BIOREFERENCE LABORATORIES||201208221418|||F||||OBX|1|NM|2194-9^LIPOPROT. (LDL) DIRECT^BRLI^18262-6^CHOLESTEROL.IN LDL^LOINC||101|mg/dL|<100|H|||F||82565,84478,83716|201208221418MSH|^~&\|BioRefHMODownload-H|BIO-REFERENCE LABS|02/01/2013 -> 02/01/2013|1200239^|201302011340||ORU^R01|20130201134016.7|P|2.3|1||NE|NEPID|7||100442149|RE17925K       |ABREU^JOSE||19480425|M|||4105 95 ST 4B^^ELMHURST^NY^11373||3476658438|||||||||UNTE|1|P|PATIENT FASTINGOBR|1|RE17925K       |100442149|0009-1^Lipid Screen(Basic Lipid Profile)||201210060000|201210060000|||||||201210062327||H46088^GARCIA^MARCO A^|(718)803-8463|80061||BIOREFERENCE LABORATORIES||201210070645|||F||||OBX|1|NM|0058-8^Cholesterol^BRLI^2093-3^CHOLESTEROL^LOINC||89|mg/dL|<200||||F||82465|201210070645OBX|2|NM|0059-6^HDL CHOL., DIRECT^BRLI^2085-9^CHOLESTEROL.IN HDL^LOINC||21||>40|L|||F||83718|201210070645OBX|3|NM|0155-2^Triglycerides^BRLI^2571-8^TRIGLYCERIDE^LOINC||54|mg/dL|<150||||F||84478|201210070645OBX|4|NM|1764-0^HDL as % of Cholesterol^BRLI^2095-8^CHOLESTEROL.IN HDL/CHOLESTEROL.TOTAL^LOINC||24|%|>14||||F||83718.01|201210070645NTE|1|L|Evaluation: AVERAGE RISKOBX|5|NM|1421-7^Chol/HDL Ratio^BRLI^9830-1^CHOLESTEROL.TOTAL/CHOLESTEROL.IN HDL^LOINC||4.2||<7.4||||F||82465.01|201210070645NTE|1|L|Evaluation: AVERAGE RISKOBX|6|NM|0253-5^LDL/HDL Ratio^BRLI^11054-4^CHOLESTEROL.IN LDL/CHOLESTEROL.IN HDL^LOINC||2.71||<3.56||||F||83720.01|201210070645OBX|7|NM|0505-8^LDL Cholesterol^BRLI^2089-1^CHOLESTEROL.IN LDL^LOINC||57|mg/dL|<100||||F||83720|201210070645OBX|8|NM|3345-6^VLDL, CALCULATED^BRLI^^^LOINC||11|mg/dL|7-32||||F||99999|201210070645OBR|2|RE17925K       |100442149|0095-0^GLUCOSE, FASTING||201210060000|201210060000|||||||201210062327||H46088^GARCIA^MARCO A^|(718)803-8463|82947||BIOREFERENCE LABORATORIES||201210070645|||F||||OBX|1|NM|0095-0^GLUCOSE, FASTING^BRLI^1558-6^GLUCOSE-POST CFST^LOINC||57|mg/dL|70-99|L|||F||82947|201210070645OBR|3|RE17925K       |100442149|0102-4^Hemoglobin A1C (Glycohgb)||201210060000|201210060000|||||||201210062327||H46088^GARCIA^MARCO A^|(718)803-8463|83036||BIOREFERENCE LABORATORIES||201210070645|||F||||OBX|1|NM|0102-4^Hemoglobin A1C^BRLI^4548-4^HEMOGLOBIN A1C/HEMOGLOBIN.TOTAL^LOINC||8.6|%|<5.7|H|||F||83036|201210070645NTE|1|L|GLYCOHEMOGLOBIN A1C AND eAG REFERENCE RANGESNTE|2|L|                         A1C(%)     DIABETES CATEGORY*NTE|3|L|                         <5.7             Normal (non-diabetic)NTE|4|L|                        5.7-6.4           Increased risk of diabetesNTE|5|L|                         =>6.5            Consistent with diabetesNTE|6|L|                         A1C(%)     eAG(ESTIMATED AVERAGE PLASMA GLUCOSE)(mg/dL)NTE|7|L|                          6                 126NTE|8|L|                          7                 154NTE|9|L|                          8                 183NTE|10|L|                          9                 212NTE|11|L|                         10                 240NTE|12|L|                         11                 269NTE|13|L|                         12                 298NTE|14|L|                   *recommended ranges-American Diabetes Association(2010)NTE|15|L|NOTE: Previous reference range 4-6%OBR|4|RE17925K       |100442149|0153-7^Thyroid Stimulating Hormone (TSH)||201210060000|201210060000|||||||201210062327||H46088^GARCIA^MARCO A^|(718)803-8463|84443||BIOREFERENCE LABORATORIES||201210070645|||F||||OBX|1|NM|0153-7^TSH^BRLI^3016-3^THYROTROPIN^LOINC||1.670|uIU/mL|0.270-4.200||||F||84443|201210070645OBR|5|RE17925K       |100442149|0399-6^CBC W/DIFF, PLATELET CT.||201210060000|201210060000|||||||201210062327||H46088^GARCIA^MARCO A^|(718)803-8463|85025||BIOREFERENCE LABORATORIES||201210070645|||F||||OBX|1|NM|1497-7^WBC^BRLI^6690-2^LEUKOCYTES^LOINC||6.36|x10(3)/uL|3.40-11.80||||F||85048|201210070645OBX|2|NM|1498-5^RBC^BRLI^789-8^ERYTHROCYTES^LOINC||4.23|x10(6)/uL|4.20-5.90||||F||85041|201210070645OBX|3|NM|1499-3^HGB^BRLI^718-7^HEMOGLOBIN^LOINC||12.9|gm/dL|12.3-17.0||||F||85018|201210070645OBX|4|NM|0019-0^HCT^BRLI^4544-3^HEMATOCRIT^LOINC||38.1|%|39.3-52.5|L|||F||85014|201210070645OBX|5|NM|1503-2^MCV^BRLI^787-2^MEAN CORPUSCULAR VOLUME^LOINC||90.1|fL|80.0-100.0||||F||85025.02|201210070645OBX|6|NM|1504-0^MCH^BRLI^785-6^ERYTHROCYTE MEAN CORPUSCULAR HEMOGLOBIN^LOINC||30.5|pg|25.0-34.1||||F||85025.03|201210070645OBX|7|NM|1502-4^MCHC^BRLI^786-4^ERYTHROCYTE MEAN CORPUSCULAR HEMOGLOBIN CONCENTRAT^LOINC||33.9|gm/dL|29.0-35.0||||F||85025.01|201210070645OBX|8|NM|1598-2^RDW^BRLI^788-0^ERYTHROCYTE DISTRIBUTION WIDTH^LOINC||13.3|%|10.9-16.9||||F||85029|201210070645OBX|9|NM|1505-7^POLYS^BRLI^31160-5^POLYMORPHONUCLEAR CELLS/100 LEUKOCYTES^LOINC||79.9|%|36.0-78.0|H|||F||85025.04|201210070645OBX|10|NM|1507-3^LYMPHS^BRLI^736-9^LYMPHOCYTES/100 LEUKOCYTES^LOINC||11.6|%|12.0-48.0|L|||F||85025.06|201210070645OBX|11|NM|1511-5^MONOS^BRLI^51384-6^Mononuclear cells/100 leukocytes^LOINC||7.9|%|0.0-13.0||||F||85025.10|201210070645OBX|12|NM|1509-9^EOS^BRLI^713-8^EOSINOPHILS/100 LEUKOCYTES^LOINC||0.2|%|0.0-8.0||||F||85025.08|201210070645OBX|13|NM|1510-7^BASOS^BRLI^706-2^BASOPHILS/100 LEUKOCYTES^LOINC||0.2|%|0.0-2.0||||F||85025.09|201210070645OBX|14|NM|270053-2^IMMATURE GRANULOCYTES^BRLI^38518-7^GRANULOCYTES.IMMATURE/100 LEUKOCYTES^LOINC||0.2|%|0.0-1.6||||F|||201210070645OBX|15|NM|0128-9^PLATELET COUNT^BRLI^777-3^PLATELETS^LOINC||160|x10(3)/uL|144-400||||F||85595|201210070645OBX|16|NM|400053-5^MPV^BRLI^32623-1^PLATELET MEAN VOLUME^LOINC||10.3|fL|8.2-11.9||||F|||201210070645NTE|1|L|NOTE: One or more parameters of the CBC reported for this accession require aNTE|2|L|MANUAL peripheral smear differential review and/or cell count. This has beenNTE|3|L|performed as per our protocol and commented on the report, if necessary. ThisNTE|4|L|review also included RBC morphology and platelet estimation.OBR|6|RE17925K       |100442149|0459-8^Urinalysis, Routine (w/micros)||201210060000|201210060000|||||||201210062327||H46088^GARCIA^MARCO A^|(718)803-8463|81001||BIOREFERENCE LABORATORIES||201210070645|||F||||OBX|1|ST|6315-6^Color^BRLI^5778-6^COLOR^LOINC||YELLOW||YELLOW, STRAW, AMBER|N|||F||99999|201210070645OBX|2|ST|6316-4^Character^BRLI^19244-3^CHARACTER^LOINC||CLEAR||CLEAR|N|||F||99999|201210070645OBX|3|NM|1520-6^Specific Gravity URN^BRLI^2965-2^SPECIFIC GRAVITY^LOINC||1.015||1.003 - 1.030||||F||81001.03|201210070645OBX|4|NM|1521-4^pH Urine^BRLI^2756-5^PH^LOINC||5.0||5.0 - 8.0||||F||81001.04|201210070645OBX|5|ST|1522-2^Protein, Urine^BRLI^20454-5^PROTEIN^LOINC||NEGATIVE||NEGATIVE|N|||F||81001.05|201210070645OBX|6|ST|1523-0^Glucose, Urine^BRLI^25428-4^GLUCOSE^LOINC||NEGATIVE||NEGATIVE|N|||F||81001.06|201210070645OBX|7|ST|1524-8^Ketone, Urine^BRLI^2514-8^KETONES^LOINC||NEGATIVE||NEGATIVE|N|||F||81001.07|201210070645OBX|8|NM|1525-5^Urobilinogen Urine^BRLI^19161-9^UROBILINOGEN^LOINC||0.2|Units|0.2 - 1.0||||F||81001.08|201210070645OBX|9|ST|1526-3^Bilirubin, Urine^BRLI^5770-3^BILIRUBIN^LOINC||NEGATIVE||NEGATIVE|N|||F||81001.09|201210070645OBX|10|ST|1527-1^Blood, Urine^BRLI^5794-3^HEMOGLOBIN^LOINC||NEGATIVE||NEGATIVE|N|||F||81001.1|201210070645OBX|11|ST|1528-9^Nitrites Urine^BRLI^5802-4^NITRITE^LOINC||NEGATIVE||NEGATIVE|N|||F||81001.11|201210070645OBX|12|ST|6311-5^Leukocyte Esterase^BRLI^5799-2^LEUKOCYTE ESTERASE^LOINC||NEGATIVE||NEGATIVE|N|||F||99999|201210070645OBX|13|ST|1529-7^Crystals Urine^BRLI^5782-8^CRYSTALS^LOINC||NONE||NONE|N|||F||81001.12|201210070645OBX|14|ST|2135-2^Crystal Amt. Urine^BRLI^5782-8^URINE CRYSTAL AMT.^LOINC||NONE||NONE|N|||F||81000.34|201210070645OBX|15|ST|1534-7^WBC, Urine^BRLI^5821-4^LEUKOCYTES^LOINC||0-4|PERHPF|0-4|N|||F||81001.17|201210070645OBX|16|ST|1535-4^RBC, Urine^BRLI^13945-1^ERYTHROCYTES^LOINC||NONE SEEN|PERHPF|NONE SEEN|N|||F||81001.18|201210070645OBX|17|ST|1546-1^Epithelial Cells, Ur^BRLI^20453-7^EPITHELIAL CELLS^LOINC||NONE||FEW|N|||F||81001.28|201210070645NTE|1|L|NTE|2|L|NOTE:  Significant quantities of epithelial cells willNTE|3|L|be identified if they are not squamous cell types.OBX|18|ST|1545-3^Cast, Hyaline, Urine^BRLI^5796-8^HYALINE CASTS^LOINC||0-4|PERLPF|0-4|N|||F||81001.27|201210070645OBX|19|ST|1547-9^Cast, Granular, Urin^BRLI^5793-5^GRANULAR CASTS^LOINC||NONE SEEN|PERLPF|0-1|N|||F||81001.29|201210070645OBX|20|ST|1543-8^Cast, RBC, Urine^BRLI^5807-3^ERYTHROCYTE CASTS^LOINC||NONE SEEN|PERLPF|0-1|N|||F||81001.25|201210070645OBX|21|ST|1549-5^Bacteria, Urine^BRLI^25145-4^BACTERIA^LOINC||NONE||FEW|N|||F||81001.31|201210070645OBR|7|RE17925K       |100442149|1440-7^DIFF.,SCREEN(no ct.)MORPH/PLAT||201210060000|201210060000|||||||201210062327||H46088^GARCIA^MARCO A^|(718)803-8463|85008,85008||BIOREFERENCE LABORATORIES||201210070645|||F||||OBX|1|NM|1497-7^WBC^BRLI^6690-2^LEUKOCYTES^LOINC||6.36|x10(3)/uL|3.40-11.80||||F||85048|201210070645OBX|2|NM|1498-5^RBC^BRLI^789-8^ERYTHROCYTES^LOINC||4.23|x10(6)/uL|4.20-5.90||||F||85041|201210070645OBX|3|NM|1499-3^HGB^BRLI^718-7^HEMOGLOBIN^LOINC||12.9|gm/dL|12.3-17.0||||F||85018|201210070645OBX|4|NM|0019-0^HCT^BRLI^4544-3^HEMATOCRIT^LOINC||38.1|%|39.3-52.5|L|||F||85014|201210070645OBX|5|NM|1503-2^MCV^BRLI^787-2^MEAN CORPUSCULAR VOLUME^LOINC||90.1|fL|80.0-100.0||||F||85025.02|201210070645OBX|6|NM|1504-0^MCH^BRLI^785-6^ERYTHROCYTE MEAN CORPUSCULAR HEMOGLOBIN^LOINC||30.5|pg|25.0-34.1||||F||85025.03|201210070645OBX|7|NM|1502-4^MCHC^BRLI^786-4^ERYTHROCYTE MEAN CORPUSCULAR HEMOGLOBIN CONCENTRAT^LOINC||33.9|gm/dL|29.0-35.0||||F||85025.01|201210070645OBX|8|NM|1598-2^RDW^BRLI^788-0^ERYTHROCYTE DISTRIBUTION WIDTH^LOINC||13.3|%|10.9-16.9||||F||85029|201210070645OBX|9|NM|1505-7^POLYS^BRLI^31160-5^POLYMORPHONUCLEAR CELLS/100 LEUKOCYTES^LOINC||79.9|%|36.0-78.0|H|||F||85025.04|201210070645OBX|10|NM|1507-3^LYMPHS^BRLI^736-9^LYMPHOCYTES/100 LEUKOCYTES^LOINC||11.6|%|12.0-48.0|L|||F||85025.06|201210070645OBX|11|NM|1509-9^EOS^BRLI^713-8^EOSINOPHILS/100 LEUKOCYTES^LOINC||0.2|%|0.0-8.0||||F||85025.08|201210070645OBX|12|NM|1510-7^BASOS^BRLI^706-2^BASOPHILS/100 LEUKOCYTES^LOINC||0.2|%|0.0-2.0||||F||85025.09|201210070645OBX|13|NM|1511-5^MONOS^BRLI^51384-6^Mononuclear cells/100 leukocytes^LOINC||7.9|%|0.0-13.0||||F||85025.10|201210070645OBX|14|NM|0128-9^PLATELET COUNT^BRLI^777-3^PLATELETS^LOINC||160|x10(3)/uL|144-400||||F||85595|201210070645OBR|8|RE17925K       |100442149|2555-1^BASIC METABOLIC||201210060000|201210060000|||||||201210062327||H46088^GARCIA^MARCO A^|(718)803-8463|80048||BIOREFERENCE LABORATORIES||201210070645|||F||||OBX|1|NM|0049-7^BUN^BRLI^3094-0^UREA NITROGEN^LOINC||16|mg/dL|8-23||||F||84520|201210070645OBX|2|NM|0050-5^Calcium^BRLI^17861-6^CALCIUM^LOINC||9.0|mg/dL|8.6-10.2||||F||82310|201210070645OBX|3|NM|0052-1^CO2^BRLI^2028-9^CARBON DIOXIDE^LOINC||25|mmol/L|22-29||||F||82374|201210070645OBX|4|NM|0057-0^Chloride^BRLI^2075-0^CHLORIDE^LOINC||104|mmol/L|96-108||||F||82435|201210070645OBX|5|NM|0070-3^Creatinine^BRLI^2160-0^CREATININE^LOINC||0.93|mg/dL|0.80-1.30||||F||82565|201210070645OBX|6|NM|0095-0^GLUCOSE, FASTING^BRLI^1558-6^GLUCOSE-POST CFST^LOINC||57|mg/dL|70-99|L|||F||82947|201210070645OBX|7|NM|0129-7^Potassium^BRLI^2823-3^POTASSIUM^LOINC||3.6|mmol/L|3.3-5.3||||F||84132|201210070645OBX|8|NM|0148-7^Sodium^BRLI^2951-2^SODIUM^LOINC||141|mmol/L|133-145||||F||84295|201210070645OBX|9|NM|1427-4^BUN/Creat Ratio^BRLI^3097-3^UREA NITROGEN/CREATININE^LOINC||17.2||10.0-28.0||||F||G0059.01|201210070645OBX|10|NM|1976-0^Glucose^BRLI^2345-7^GLUCOSE^LOINC||59|mg/dL|70-99|L|||F||82947.01|201210070645OBX|11|NM|090013-4^e-GFR^BRLI^^^LOINC||82|mL/min|>60||||F|||201210070645OBX|12|NM|090015-9^e-GFR, African American^BRLI^^^LOINC||99|mL/min|>60||||F|||201210070645MSH|^~&\|BioRefHMODownload-H|BIO-REFERENCE LABS|02/01/2013 -> 02/01/2013|1200239^|201302011340||ORU^R01|20130201134016.8|P|2.3|1||NE|NEPID|8|13472|107030705|AG08993K       |ACEVEDO^AURORA||19550714|F|||167 MAIN STREET^^GOSHEN^NY^10924||8459785624||||||NTE|1|P|NON FASTINGOBR|1|AG08993K       |107030705|0009-1^Lipid Screen(Basic Lipid Profile)||201203061458|201203061458|||||||201203062337||G11486^SHETH^VIRAL^|(845)294-7700|80061||BIOREFERENCE LABORATORIES||201203070348|||F||||OBX|1|NM|0058-8^Cholesterol^BRLI^2093-3^CHOLESTEROL^LOINC||244|mg/dL|<200|H|||F||82465|201203070348OBX|2|NM|0059-6^HDL CHOL., DIRECT^BRLI^2085-9^CHOLESTEROL.IN HDL^LOINC||34||>50|L|||F||83718|201203070348OBX|3|NM|0155-2^Triglycerides^BRLI^2571-8^TRIGLYCERIDE^LOINC||238|mg/dL|<150|H|||F||84478|201203070348OBX|4|NM|1764-0^HDL as % of Cholesterol^BRLI^2095-8^CHOLESTEROL.IN HDL/CHOLESTEROL.TOTAL^LOINC||14|%|>14|A|||F|||201203070348NTE|1|L|Evaluation: ABOVE AVG.(MODERATE RISK)OBX|5|NM|1421-7^Chol/HDL Ratio^BRLI^9830-1^CHOLESTEROL.TOTAL/CHOLESTEROL.IN HDL^LOINC||7.2||<5.8|A|||F|||201203070348NTE|1|L|Evaluation: ABOVE AVG.(MODERATE RISK)OBX|6|NM|0253-5^LDL/HDL Ratio^BRLI^11054-4^CHOLESTEROL.IN LDL/CHOLESTEROL.IN HDL^LOINC||5.12||<3.56|H|||F|||201203070348OBX|7|NM|3345-6^VLDL, CALCULATED^BRLI^^^LOINC||48|mg/dL|7-32|H|||F||99999|201203070348OBR|2|AG08993K       |107030705|0068-7^CPK (CK), TOTAL||201203061458|201203061458|||||||201203062337||G11486^SHETH^VIRAL^|(845)294-7700|82550||BIOREFERENCE LABORATORIES||201203070348|||F||||OBX|1|NM|0068-7^CK^BRLI^2157-6^CREATINE KINASE^LOINC||37|U/L|26-192||||F||82550|201203070348OBR|3|AG08993K       |107030705|0102-4^Hemoglobin A1C (Glycohgb)||201203061458|201203061458|||||||201203062337||G11486^SHETH^VIRAL^|(845)294-7700|83036||BIOREFERENCE LABORATORIES||201203070348|||F||||OBX|1|NM|0102-4^Hemoglobin A1C^BRLI^4548-4^HEMOGLOBIN A1C/HEMOGLOBIN.TOTAL^LOINC||11.7|%|<5.7|H|||F||83036|201203070348NTE|1|L|GLYCOHEMOGLOBIN A1C AND eAG REFERENCE RANGESNTE|2|L|                         A1C(%)     DIABETES CATEGORY*NTE|3|L|                         <5.7             Normal (non-diabetic)NTE|4|L|                        5.7-6.4           Increased risk of diabetesNTE|5|L|                         =>6.5            Consistent with diabetesNTE|6|L|                         A1C(%)     eAG(ESTIMATED AVERAGE PLASMA GLUCOSE)(mg/dL)NTE|7|L|                          6                 126NTE|8|L|                          7                 154NTE|9|L|                          8                 183NTE|10|L|                          9                 212NTE|11|L|                         10                 240NTE|12|L|                         11                 269NTE|13|L|                         12                 298NTE|14|L|                   *recommended ranges-American Diabetes Association(2010)NTE|15|L|NOTE: Previous reference range 4-6%OBR|4|AG08993K       |107030705|2195-6^LDL Cholesterol, Direct||201203061458|201203061458|||||||201203062337||G11486^SHETH^VIRAL^|(845)294-7700|83721||BIOREFERENCE LABORATORIES||201203070348|||F||||OBX|1|NM|2194-9^LIPOPROT. (LDL) DIRECT^BRLI^18262-6^CHOLESTEROL.IN LDL^LOINC||174|mg/dL|<100|H|||F|||201203070348OBR|5|AG08993K       |107030705|3422-3^Hepatic Function Panel||201203061458|201203061458|||||||201203062337||G11486^SHETH^VIRAL^|(845)294-7700|80076||BIOREFERENCE LABORATORIES||201203070348|||F||||OBX|1|NM|0033-1^Albumin^BRLI^1751-7^ALBUMIN^LOINC||4.2|g/dL|3.5-5.2||||F||82040|201203070348OBX|2|NM|0043-0^Bilirubin, Total^BRLI^1975-2^BILIRUBIN^LOINC||0.5|mg/dL|0.1-1.0||||F||82247|201203070348OBX|3|NM|0044-8^Bilirubin, Direct^BRLI^15152-2^BILIRUBIN.GLUCURONIDATED^LOINC||0.1|mg/dL|0.0-0.3||||F||82248|201203070348OBX|4|NM|0135-4^Total Protein^BRLI^2885-2^PROTEIN^LOINC||6.6|g/dL|5.9-8.4||||F||84155|201203070348OBX|5|NM|0146-1^AST^BRLI^1920-8^ASPARTATE AMINOTRANSFERASE^LOINC||17|U/L|<32||||F||84450|201203070348OBX|6|NM|0147-9^ALT^BRLI^1742-6^ALANINE AMINOTRANSFERASE^LOINC||16|U/L|<33||||F||84460|201203070348OBX|7|NM|0185-9^Alk Phos^BRLI^6768-6^ALKALINE PHOSPHATASE^LOINC||108|U/L|35-104|H|||F||84075|201203070348OBX|8|NM|0641-1^A/G Ratio^BRLI^1759-0^ALBUMIN/GLOBULIN^LOINC||1.8||1.1-2.9||||F|||201203070348OBX|9|NM|1753-3^Globulin^BRLI^2336-6^GLOBULIN^LOINC||2.4|g/dL|1.7-3.7||||F|||201203070348OBX|10|NM|3774-7^Bilirubin, Indirect^BRLI^1971-1^BILIRUBIN.NON-GLUCURONIDATED^LOINC||0.4|mg/dL|0.1-1.0||||F||99999|201203070348OBR|6|AG08993K       |107030705|3427-2^Comprehensive Metabolic Panel||201203061458|201203061458|||||||201203062337||G11486^SHETH^VIRAL^|(845)294-7700|80099||BIOREFERENCE LABORATORIES||201203070348|||F||||OBX|1|NM|0135-4^Total Protein^BRLI^2885-2^PROTEIN^LOINC||6.6|g/dL|5.9-8.4||||F||84155|201203070348OBX|2|NM|0033-1^Albumin^BRLI^1751-7^ALBUMIN^LOINC||4.2|g/dL|3.5-5.2||||F||82040|201203070348OBX|3|NM|1753-3^Globulin^BRLI^2336-6^GLOBULIN^LOINC||2.4|g/dL|1.7-3.7||||F|||201203070348OBX|4|NM|0641-1^A/G Ratio^BRLI^1759-0^ALBUMIN/GLOBULIN^LOINC||1.8||1.1-2.9||||F|||201203070348OBX|5|NM|0148-7^Sodium^BRLI^2951-2^SODIUM^LOINC||135|mmol/L|133-145||||F||84295|201203070348OBX|6|NM|0129-7^Potassium^BRLI^2823-3^POTASSIUM^LOINC||4.2|mmol/L|3.3-5.3||||F||84132|201203070348OBX|7|NM|0057-0^Chloride^BRLI^2075-0^CHLORIDE^LOINC||96|mmol/L|96-108||||F||82435|201203070348OBX|8|NM|0052-1^CO2^BRLI^2028-9^CARBON DIOXIDE^LOINC||28|mmol/L|22-29||||F||82374|201203070348OBX|9|NM|0049-7^BUN^BRLI^3094-0^UREA NITROGEN^LOINC||11|mg/dL|6-20||||F||84520|201203070348OBX|10|NM|0070-3^Creatinine^BRLI^2160-0^CREATININE^LOINC||0.44|mg/dL|0.60-1.10|L|||F||82565|201203070348NTE|1|L|NOTE: The creatinine reference ranges have changed effective 11/7/11.OBX|11|NM|090013-4^e-GFR^BRLI^^^LOINC||148|mL/min|>60||||F|||201203070348OBX|12|NM|090015-9^e-GFR, African American^BRLI^^^LOINC||179|mL/min|>60||||F|||201203070348OBX|13|NM|1427-4^BUN/Creat Ratio^BRLI^3097-3^UREA NITROGEN/CREATININE^LOINC||25.0||10.0-28.0||||F|||201203070348OBX|14|NM|0050-5^Calcium^BRLI^17861-6^CALCIUM^LOINC||9.3|mg/dL|8.6-10.2||||F||82310|201203070348OBX|15|NM|0043-0^Bilirubin, Total^BRLI^1975-2^BILIRUBIN^LOINC||0.5|mg/dL|0.1-1.0||||F||82247|201203070348OBX|16|NM|0185-9^Alk Phos^BRLI^6768-6^ALKALINE PHOSPHATASE^LOINC||108|U/L|35-104|H|||F||84075|201203070348OBX|17|NM|0146-1^AST^BRLI^1920-8^ASPARTATE AMINOTRANSFERASE^LOINC||17|U/L|<32||||F||84450|201203070348OBX|18|NM|0147-9^ALT^BRLI^1742-6^ALANINE AMINOTRANSFERASE^LOINC||16|U/L|<33||||F||84460|201203070348OBX|19|NM|1976-0^Glucose^BRLI^2345-7^GLUCOSE^LOINC||236|mg/dL|70-99|H|||F|||201203070348OBR|7|AG08993K       |107030705|MESS^* MESSAGES *||201203061458|201203061458|||||||201203062337||G11486^SHETH^VIRAL^|(845)294-7700|||BIOREFERENCE LABORATORIES||201203070348|||F||||OBX|1|ST|MESS^* MESSAGES *^BRLI^^^LOINC||SEE BELOW||SEE BELOW|N|||F|||201203070348NTE|1|L|NTE|2|L|NOTE: Specimen submitted is LIPEMIC. This may cause inaccurate results.NTE|3|L|      Please resubmit a fasting specimen at your earliest convenience.MSH|^~&\|BioRefHMODownload-H|BIO-REFERENCE LABS|02/01/2013 -> 02/01/2013|1200239^|201302011340||ORU^R01|20130201134016.9|P|2.3|1||NE|NEPID|9|501|107475737|AG08993K       |ACEVEDO^AURORA||19550714|F|||121 DUNNING RD^^MIDDLETOWN^NY^10940||||||||OBR|1|AG08993K       |107475737|0102-4^Hemoglobin A1C (Glycohgb)||201204040535|201204040535|||||||201204041057||102466^YEDDU, MRILINI|(845)343-0801|83036||BIOREFERENCE LABORATORIES||201204041514|||F||||OBX|1|NM|0102-4^Hemoglobin A1C^BRLI^4548-4^HEMOGLOBIN A1C/HEMOGLOBIN.TOTAL^LOINC||11.2|%|<5.7|H|||F||83036|201204041514NTE|1|L|GLYCOHEMOGLOBIN A1C AND eAG REFERENCE RANGESNTE|2|L|                         A1C(%)     DIABETES CATEGORY*NTE|3|L|                         <5.7             Normal (non-diabetic)NTE|4|L|                        5.7-6.4           Increased risk of diabetesNTE|5|L|                         =>6.5            Consistent with diabetesNTE|6|L|                         A1C(%)     eAG(ESTIMATED AVERAGE PLASMA GLUCOSE)(mg/dL)NTE|7|L|                          6                 126NTE|8|L|                          7                 154NTE|9|L|                          8                 183NTE|10|L|                          9                 212NTE|11|L|                         10                 240NTE|12|L|                         11                 269NTE|13|L|                         12                 298NTE|14|L|                   *recommended ranges-American Diabetes Association(2010)NTE|15|L|NOTE: Previous reference range 4-6%OBR|2|AG08993K       |107475737|0399-6^CBC W/DIFF, PLATELET CT.||201204040535|201204040535|||||||201204041057||102466^YEDDU, MRILINI|(845)343-0801|85025||BIOREFERENCE LABORATORIES||201204041514|||F||||OBX|1|NM|1497-7^WBC^BRLI^6690-2^LEUKOCYTES^LOINC||7.42|x10(3)/uL|3.40-11.80||||F||85048|201204041514OBX|2|NM|1498-5^RBC^BRLI^789-8^ERYTHROCYTES^LOINC||5.59|x10(6)/uL|3.60-5.50|H|||F||85041|201204041514OBX|3|NM|1499-3^HGB^BRLI^718-7^HEMOGLOBIN^LOINC||14.1|gm/dL|11.5-15.6||||F||85018|201204041514OBX|4|NM|0019-0^HCT^BRLI^4544-3^HEMATOCRIT^LOINC||43.7|%|34.5-46.5||||F||85014|201204041514OBX|5|NM|1503-2^MCV^BRLI^787-2^MEAN CORPUSCULAR VOLUME^LOINC||78.2|fL|80.0-100.0|L|||F|||201204041514OBX|6|NM|1504-0^MCH^BRLI^785-6^ERYTHROCYTE MEAN CORPUSCULAR HEMOGLOBIN^LOINC||25.2|pg|25.0-34.1||||F|||201204041514OBX|7|NM|1502-4^MCHC^BRLI^786-4^ERYTHROCYTE MEAN CORPUSCULAR HEMOGLOBIN CONCENTRAT^LOINC||32.3|gm/dL|29.0-35.0||||F|||201204041514OBX|8|NM|1598-2^RDW^BRLI^788-0^ERYTHROCYTE DISTRIBUTION WIDTH^LOINC||14.1|%|10.9-16.9||||F||85029|201204041514OBX|9|NM|1505-7^POLYS^BRLI^31160-5^POLYMORPHONUCLEAR CELLS/100 LEUKOCYTES^LOINC||43.0|%|36.0-78.0||||F|||201204041514OBX|10|NM|1507-3^LYMPHS^BRLI^736-9^LYMPHOCYTES/100 LEUKOCYTES^LOINC||43.9|%|12.0-48.0||||F|||201204041514OBX|11|NM|1511-5^MONOS^BRLI^51384-6^Mononuclear cells/100 leukocytes^LOINC||11.2|%|0.0-13.0||||F|||201204041514OBX|12|NM|1509-9^EOS^BRLI^713-8^EOSINOPHILS/100 LEUKOCYTES^LOINC||1.3|%|0.0-8.0||||F|||201204041514OBX|13|NM|1510-7^BASOS^BRLI^706-2^BASOPHILS/100 LEUKOCYTES^LOINC||0.3|%|0.0-2.0||||F|||201204041514OBX|14|NM|270053-2^IMMATURE GRANULOCYTES^BRLI^38518-7^GRANULOCYTES.IMMATURE/100 LEUKOCYTES^LOINC||0.3|%|0.0-1.6||||F|||201204041514OBX|15|NM|0128-9^PLATELET COUNT^BRLI^777-3^PLATELETS^LOINC||150|x10(3)/uL|144-400||||F||85595|201204041514OBX|16|ST|400053-5^MPV^BRLI^32623-1^PLATELET MEAN VOLUME^LOINC||Not Measured|fL|8.2-11.9|N|||F|||201204041514NTE|1|L|NOTE: Giant platelets measuring >40 fL cannot be reliably assessed due toNTE|2|L|      size overlap with red blood cell fragments, and are not reported.OBR|3|AG08993K       |107475737|3427-2^Comprehensive Metabolic Panel||201204040535|201204040535|||||||201204041057||102466^YEDDU, MRILINI|(845)343-0801|80099||BIOREFERENCE LABORATORIES||201204041514|||F||||OBX|1|NM|0135-4^Total Protein^BRLI^2885-2^PROTEIN^LOINC||5.9|g/dL|5.9-8.4||||F||84155|201204041514OBX|2|NM|0033-1^Albumin^BRLI^1751-7^ALBUMIN^LOINC||3.7|g/dL|3.5-5.2||||F||82040|201204041514OBX|3|NM|1753-3^Globulin^BRLI^2336-6^GLOBULIN^LOINC||2.2|g/dL|1.7-3.7||||F|||201204041514OBX|4|NM|0641-1^A/G Ratio^BRLI^1759-0^ALBUMIN/GLOBULIN^LOINC||1.7||1.1-2.9||||F|||201204041514OBX|5|NM|0148-7^Sodium^BRLI^2951-2^SODIUM^LOINC||134|mmol/L|133-145||||F||84295|201204041514OBX|6|NM|0129-7^Potassium^BRLI^2823-3^POTASSIUM^LOINC||4.3|mmol/L|3.3-5.3||||F||84132|201204041514OBX|7|NM|0057-0^Chloride^BRLI^2075-0^CHLORIDE^LOINC||101|mmol/L|96-108||||F||82435|201204041514OBX|8|NM|0052-1^CO2^BRLI^2028-9^CARBON DIOXIDE^LOINC||22|mmol/L|22-29||||F||82374|201204041514OBX|9|NM|0049-7^BUN^BRLI^3094-0^UREA NITROGEN^LOINC||21|mg/dL|6-20|H|||F||84520|201204041514OBX|10|NM|0070-3^Creatinine^BRLI^2160-0^CREATININE^LOINC||0.51|mg/dL|0.60-1.10|L|||F||82565|201204041514NTE|1|L|NOTE: The creatinine reference ranges have changed effective 11/7/11.OBX|11|NM|090013-4^e-GFR^BRLI^^^LOINC||125|mL/min|>60||||F|||201204041514OBX|12|NM|090015-9^e-GFR, African American^BRLI^^^LOINC||151|mL/min|>60||||F|||201204041514OBX|13|NM|1427-4^BUN/Creat Ratio^BRLI^3097-3^UREA NITROGEN/CREATININE^LOINC||41.2||10.0-28.0|H|||F|||201204041514OBX|14|NM|0050-5^Calcium^BRLI^17861-6^CALCIUM^LOINC||8.9|mg/dL|8.6-10.2||||F||82310|201204041514OBX|15|NM|0043-0^Bilirubin, Total^BRLI^1975-2^BILIRUBIN^LOINC||0.2|mg/dL|0.1-1.0||||F||82247|201204041514OBX|16|NM|0185-9^Alk Phos^BRLI^6768-6^ALKALINE PHOSPHATASE^LOINC||105|U/L|35-104|H|||F||84075|201204041514OBX|17|NM|0146-1^AST^BRLI^1920-8^ASPARTATE AMINOTRANSFERASE^LOINC||11|U/L|<32||||F||84450|201204041514OBX|18|NM|0147-9^ALT^BRLI^1742-6^ALANINE AMINOTRANSFERASE^LOINC||13|U/L|<33||||F||84460|201204041514OBX|19|NM|1976-0^Glucose^BRLI^2345-7^GLUCOSE^LOINC||265|mg/dL|70-99|H|||F|||201204041514MSH|^~&\|BioRefHMODownload-H|BIO-REFERENCE LABS|02/01/2013 -> 02/01/2013|1200239^|201302011340||ORU^R01|20130201134016.10|P|2.3|1||NE|NEPID|10|13472|108137500|AG08993K       |ACEVEDO^AURORA||19550714|F|||167 MAIN STREET^^GOSHEN^NY^10924||8459785624||||||NTE|1|P|NON FASTINGOBR|1|AG08993K       |108137500|0009-1^Lipid Screen(Basic Lipid Profile)||201205101322|201205101322|||||||201205102307||G11486^SHETH^VIRAL^|(845)294-7700|80061||BIOREFERENCE LABORATORIES||201205110818|||F||||OBX|1|NM|0058-8^Cholesterol^BRLI^2093-3^CHOLESTEROL^LOINC||171|mg/dL|<200||||F||82465|201205110818OBX|2|NM|0059-6^HDL CHOL., DIRECT^BRLI^2085-9^CHOLESTEROL.IN HDL^LOINC||41||>50|L|||F||83718|201205110818OBX|3|NM|0155-2^Triglycerides^BRLI^2571-8^TRIGLYCERIDE^LOINC||230|mg/dL|<150|H|||F||84478|201205110818OBX|4|NM|1764-0^HDL as % of Cholesterol^BRLI^2095-8^CHOLESTEROL.IN HDL/CHOLESTEROL.TOTAL^LOINC||24|%|>14||||F|||201205110818NTE|1|L|Evaluation: AVERAGE RISKOBX|5|NM|1421-7^Chol/HDL Ratio^BRLI^9830-1^CHOLESTEROL.TOTAL/CHOLESTEROL.IN HDL^LOINC||4.2||<5.8||||F|||201205110818NTE|1|L|Evaluation: AVERAGE RISKOBX|6|NM|0253-5^LDL/HDL Ratio^BRLI^11054-4^CHOLESTEROL.IN LDL/CHOLESTEROL.IN HDL^LOINC||2.61||<3.56||||F|||201205110818OBX|7|NM|3345-6^VLDL, CALCULATED^BRLI^^^LOINC||46|mg/dL|7-32|H|||F||99999|201205110818OBR|2|AG08993K       |108137500|0053-9^CBC W/ Diff, Platelets||201205101322|201205101322|||||||201205102307||G11486^SHETH^VIRAL^|(845)294-7700|85025||BIOREFERENCE LABORATORIES||201205110818|||F||||OBX|1|NM|1497-7^WBC^BRLI^6690-2^LEUKOCYTES^LOINC||7.15|x10(3)/uL|3.40-11.80||||F||85048|201205110818OBX|2|NM|1498-5^RBC^BRLI^789-8^ERYTHROCYTES^LOINC||5.66|x10(6)/uL|3.60-5.50|H|||F||85041|201205110818OBX|3|NM|1499-3^HGB^BRLI^718-7^HEMOGLOBIN^LOINC||14.5|gm/dL|11.5-15.6||||F||85018|201205110818OBX|4|NM|0019-0^HCT^BRLI^4544-3^HEMATOCRIT^LOINC||43.8|%|34.5-46.5||||F||85014|201205110818OBX|5|NM|1503-2^MCV^BRLI^787-2^MEAN CORPUSCULAR VOLUME^LOINC||77.4|fL|80.0-100.0|L|||F|||201205110818OBX|6|NM|1504-0^MCH^BRLI^785-6^ERYTHROCYTE MEAN CORPUSCULAR HEMOGLOBIN^LOINC||25.6|pg|25.0-34.1||||F|||201205110818OBX|7|NM|1502-4^MCHC^BRLI^786-4^ERYTHROCYTE MEAN CORPUSCULAR HEMOGLOBIN CONCENTRAT^LOINC||33.1|gm/dL|29.0-35.0||||F|||201205110818OBX|8|NM|1598-2^RDW^BRLI^788-0^ERYTHROCYTE DISTRIBUTION WIDTH^LOINC||14.8|%|10.9-16.9||||F||85029|201205110818OBX|9|NM|1505-7^POLYS^BRLI^31160-5^POLYMORPHONUCLEAR CELLS/100 LEUKOCYTES^LOINC||51.2|%|36.0-78.0||||F|||201205110818OBX|10|NM|1507-3^LYMPHS^BRLI^736-9^LYMPHOCYTES/100 LEUKOCYTES^LOINC||39.2|%|12.0-48.0||||F|||201205110818OBX|11|NM|1511-5^MONOS^BRLI^51384-6^Mononuclear cells/100 leukocytes^LOINC||7.7|%|0.0-13.0||||F|||201205110818OBX|12|NM|1509-9^EOS^BRLI^713-8^EOSINOPHILS/100 LEUKOCYTES^LOINC||1.3|%|0.0-8.0||||F|||201205110818OBX|13|NM|1510-7^BASOS^BRLI^706-2^BASOPHILS/100 LEUKOCYTES^LOINC||0.3|%|0.0-2.0||||F|||201205110818OBX|14|NM|270053-2^IMMATURE GRANULOCYTES^BRLI^38518-7^GRANULOCYTES.IMMATURE/100 LEUKOCYTES^LOINC||0.3|%|0.0-1.6||||F|||201205110818OBX|15|NM|0128-9^PLATELET COUNT^BRLI^777-3^PLATELETS^LOINC||129|x10(3)/uL|144-400|L|||F||85595|201205110818OBX|16|ST|400053-5^MPV^BRLI^32623-1^PLATELET MEAN VOLUME^LOINC||Not Measured|fL|8.2-11.9|N|||F|||201205110818NTE|1|L|NOTE: Giant platelets measuring >40 fL cannot be reliably assessed due toNTE|2|L|      size overlap with red blood cell fragments, and are not reported.OBR|3|AG08993K       |108137500|0068-7^CPK (CK), TOTAL||201205101322|201205101322|||||||201205102307||G11486^SHETH^VIRAL^|(845)294-7700|82550||BIOREFERENCE LABORATORIES||201205110818|||F||||OBX|1|NM|0068-7^CK^BRLI^2157-6^CREATINE KINASE^LOINC||29|U/L|26-192||||F||82550|201205110818OBR|4|AG08993K       |108137500|0102-4^Hemoglobin A1C (Glycohgb)||201205101322|201205101322|||||||201205102307||G11486^SHETH^VIRAL^|(845)294-7700|83036||BIOREFERENCE LABORATORIES||201205110818|||F||||OBX|1|NM|0102-4^Hemoglobin A1C^BRLI^4548-4^HEMOGLOBIN A1C/HEMOGLOBIN.TOTAL^LOINC||11.1|%|<5.7|H|||F||83036|201205110818NTE|1|L|GLYCOHEMOGLOBIN A1C AND eAG REFERENCE RANGESNTE|2|L|                         A1C(%)     DIABETES CATEGORY*NTE|3|L|                         <5.7             Normal (non-diabetic)NTE|4|L|                        5.7-6.4           Increased risk of diabetesNTE|5|L|                         =>6.5            Consistent with diabetesNTE|6|L|                         A1C(%)     eAG(ESTIMATED AVERAGE PLASMA GLUCOSE)(mg/dL)NTE|7|L|                          6                 126NTE|8|L|                          7                 154NTE|9|L|                          8                 183NTE|10|L|                          9                 212NTE|11|L|                         10                 240NTE|12|L|                         11                 269NTE|13|L|                         12                 298NTE|14|L|                   *recommended ranges-American Diabetes Association(2010)NTE|15|L|NOTE: Previous reference range 4-6%OBR|5|AG08993K       |108137500|0286-5^Vitamin D, 25-Hydroxy, Serum||201205101322|201205101322|||||||201205102307||G11486^SHETH^VIRAL^|(845)294-7700|82307||BIOREFERENCE LABORATORIES||201205110818|||F||||OBX|1|NM|0286-5^25OH, VITAMIN D^BRLI^62292-8^CALCIDIOL^LOINC||10.7|ng/mL|32.0-100.0|L|||F||82307|201205110818OBR|6|AG08993K       |108137500|2195-6^LDL Cholesterol, Direct||201205101322|201205101322|||||||201205102307||G11486^SHETH^VIRAL^|(845)294-7700|83721||BIOREFERENCE LABORATORIES||201205110818|||F||||OBX|1|NM|2194-9^LIPOPROT. (LDL) DIRECT^BRLI^18262-6^CHOLESTEROL.IN LDL^LOINC||107|mg/dL|<100|H|||F|||201205110818OBR|7|AG08993K       |108137500|3427-2^Comprehensive Metabolic Panel||201205101322|201205101322|||||||201205102307||G11486^SHETH^VIRAL^|(845)294-7700|80099||BIOREFERENCE LABORATORIES||201205110818|||F||||OBX|1|NM|0135-4^Total Protein^BRLI^2885-2^PROTEIN^LOINC||6.6|g/dL|5.9-8.4||||F||84155|201205110818OBX|2|NM|0033-1^Albumin^BRLI^1751-7^ALBUMIN^LOINC||4.2|g/dL|3.5-5.2||||F||82040|201205110818OBX|3|NM|1753-3^Globulin^BRLI^2336-6^GLOBULIN^LOINC||2.4|g/dL|1.7-3.7||||F|||201205110818OBX|4|NM|0641-1^A/G Ratio^BRLI^1759-0^ALBUMIN/GLOBULIN^LOINC||1.8||1.1-2.9||||F|||201205110818OBX|5|NM|0148-7^Sodium^BRLI^2951-2^SODIUM^LOINC||138|mmol/L|133-145||||F||84295|201205110818OBX|6|NM|0129-7^Potassium^BRLI^2823-3^POTASSIUM^LOINC||4.6|mmol/L|3.3-5.3||||F||84132|201205110818OBX|7|NM|0057-0^Chloride^BRLI^2075-0^CHLORIDE^LOINC||101|mmol/L|96-108||||F||82435|201205110818OBX|8|NM|0052-1^CO2^BRLI^2028-9^CARBON DIOXIDE^LOINC||21|mmol/L|22-29|L|||F||82374|201205110818OBX|9|NM|0049-7^BUN^BRLI^3094-0^UREA NITROGEN^LOINC||16|mg/dL|6-20||||F||84520|201205110818OBX|10|NM|0070-3^Creatinine^BRLI^2160-0^CREATININE^LOINC||0.57|mg/dL|0.60-1.10|L|||F||82565|201205110818NTE|1|L|NOTE: The creatinine reference ranges have changed effective 11/7/11.OBX|11|NM|090013-4^e-GFR^BRLI^^^LOINC||110|mL/min|>60||||F|||201205110818OBX|12|NM|090015-9^e-GFR, African American^BRLI^^^LOINC||133|mL/min|>60||||F|||201205110818OBX|13|NM|1427-4^BUN/Creat Ratio^BRLI^3097-3^UREA NITROGEN/CREATININE^LOINC||28.1||10.0-28.0|H|||F|||201205110818OBX|14|NM|0050-5^Calcium^BRLI^17861-6^CALCIUM^LOINC||9.0|mg/dL|8.6-10.2||||F||82310|201205110818OBX|15|NM|0043-0^Bilirubin, Total^BRLI^1975-2^BILIRUBIN^LOINC||0.2|mg/dL|0.1-1.0||||F||82247|201205110818OBX|16|NM|0185-9^Alk Phos^BRLI^6768-6^ALKALINE PHOSPHATASE^LOINC||109|U/L|35-104|H|||F||84075|201205110818OBX|17|NM|0146-1^AST^BRLI^1920-8^ASPARTATE AMINOTRANSFERASE^LOINC||16|U/L|<32||||F||84450|201205110818OBX|18|NM|0147-9^ALT^BRLI^1742-6^ALANINE AMINOTRANSFERASE^LOINC||21|U/L|<33||||F||84460|201205110818OBX|19|NM|1976-0^Glucose^BRLI^2345-7^GLUCOSE^LOINC||260|mg/dL|70-99|H|||F|||201205110818